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SUMMARY
The two main objectives of the studies described in this thesis 
were to assess the value of the recently discovered feline 
lentivirus, feline immunodeficiency virus (FIV), as a model for 
human immunodeficiency virus (HIV) infection and to use this 
model towards the development of an effective vaccine.
Chapter 1 introduces the classification of the retrovirus family 
and gives an account of certain aspects of each of the 
lentiviruses. The literature relevant to the five areas of 
epidemiology, clinical signs, diagnosis, cell tropism and vaccine 
development is reviewed for each lentivirus.
In chapter 2 the materials and methods which are used throughout 
this thesis are discussed. Specific materials and methods are 
described at the beginning of the relevant chapter.
Chapter 3 describes an epidemiological survey of the prevalence 
of FIV in the UK. Blood samples from 1204 sick and 1007 healthy 
cats of known health status, breed, age and sex were tested for 
antibodies to FIV and for feline leukaemia virus (FeLV).
The prevalence of FIV was 19% in sick cats and 6% in healthy
cats. For FeLV, the prevalence was 18% in sick cats and 5% in 
healthy cats. Both infections were found to be more common in 
domestic cats than in pedigree cats. FIV was more prevalent in 
older cats in contrast to FeLV which was more prevalent in young 
cats. Whereas there was no sex effect for FeLV, male cats were
more likely to be infected with FIV than female cats. No
epidemiological interaction was demonstrated between FIV and FeLV 
infection.
Of the cats which were in contact with FIV in multi-cat 
households, 21% had seroconverted. The prevalence of FeLV 
viraemia in cats in contact with FeLV was 14%. Those clinical 
signs which were associated with FIV were pyrexia,
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gingivitis/stomatitis and respiratory signs, and with FeLV, 
pyrexia and anaemia. It was concluded that both viruses were 
significant causes of disease, and that the groups most likely to 
be infected with FIV were older, free-roaming male cats and for 
FeLV, younger, free-roaming cats.
In chapter 4 the serological responses of cats to FIV infection 
are examined. Firstly, the proteins of FIV were identified by 
sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS- 
PAGE) and immunoblotting. Purified 35S-methionine/cysteine 
labelled virus contained proteins of Mr 120K, 24K, 17K and 10K, 
of which the most prominent were p24 and pl7, and minor 
components of 62K, 54K, 52K, 41K and 32K. Sera from FIV-infected 
cats precipitated two glycoproteins of Mr 120K (gpl20) and 41K 
(gp41) from lysates of ^C-glucosamine labelled infected cells. 
Purified virus contained very little or no detectable 
glycoproteins.
Secondly, the serological response to individual viral proteins 
was followed in experimentally infected cats by immunoblotting. 
Since purified virus was a poor source of gpl20, a method using 
FIV-infected cell lysates was developed. Cats produced antibodies 
to gpl20, p55, p24 and pi7. (The p55 was presumed to be a
precursor of p24 and pi 7.) Following infection, antibodies 
developed first to p24 and subsequently to pl7, p55 and gpl20. 
Sera from cats infected with three separate isolates of FIV, two 
from the UK and one from the USA, had cross-reacting antibodies 
to all of these viral proteins.
Thirdly, the criteria for identification of seropositive cats 
were defined. The minimum requirement for a positive immunoblot 
was antibody to gpl20 or to at least three core proteins (p55, 
p24 and pl7). Comparison of two commercial enzyme-linked 
immunosorbent assay (ELISA) kits and immunoblotting indicated 
that false positive results occurred as a result of non-specific 
reactions in the ELISA systems.
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Chapter 5 describes the initial isolation of FIV-8 followed by 
studies to optimise the production of FIV proteins for vaccine 
formulations. The in vitro cell tropism of two isolates of FIV 
was examined, both by infection with cell-free FIV-infected 
supernatants and by co-cultivation with FIV-infected cells. Q201 
cells, which were most readily infected with FIV-8, were examined 
by flow cytometric analysis for changes in expression of surface 
markers after FIV infection. As the expression of fCD4 and the 
molecule recognised by monoclonal antibody vpgl5 decreased with 
FIV-8 infection, experiments were designed to identify the 
receptor for FIV-8. Subsequently, vpgl5 was shown to block FIV-8 
infection of both Q201 cells and CRFK cells. This provided strong 
evidence that the molecule recognised by vpgl5 was the receptor 
for FIV-8.
In chapter 6 the development of a system to evaluate the efficacy 
of vaccines against FIV is described. The minimum infectious dose 
of FIV-8 was determined by titration in cats and was subsequently 
used in challenge experiments. Post-challenge, cats were 
monitored for infection by virus isolation and seroconversion 
(measured by ELISA and immunoblot). Passive immunisation of 2 
cats did not give protection against 40 infectious units of FIV. 
An immune stimulating complex (ISCOM) vaccine was constructed 
which contained FIV core proteins. A very good antibody response 
was made to the core proteins but there was no protection against 
20 infectious units of FIV.
Chapter 7 gives an account of the attempts to induce antibodies 
against the envelope glycoprotein of FIV. Lysates of infected 
cells were used as a source of gpl20. Purification of the gpl20 
using gel filtration and affinity chromatography was shown to 
be very inefficient. Therefore a vaccine was constructed which 
contained fixed, inactivated FIV-infected cells. Animals 
vaccinated with this preparation produced antibodies against the 
envelope proteins of FIV but only low levels of virus 
neutralising antibodies were achieved. None of the vaccinated
13
cats were protected against challenge with 20 infectious units of 
FIV.
Chapter 8 is a general discussion which reviews the results in 
this thesis and compares them with those of experiments by 
others. The advantages of FIV as an animal model for HIV are 
discussed and suggestions for future work are proposed.
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1. INTRODUCTION
This thesis describes studies which were undertaken to assess 
feline immunodeficiency virus (FIV) as a model for human 
immunodeficiency virus (HIV) infection. The areas which were 
investigated were the epidemiology of FIV infection, the 
serological response to the infection and its diagnosis and the 
cell tropism of FIV. The final part of the thesis describes 
studies towards the development of a vacccine against FIV.
FIV belongs to the lentivirus subfamily in the retrovirus family. 
The virus was first isolated from cats suffering from a condition 
similar to that seen previously in humans with acquired 
immunodeficiency syndrome (AIDS) [1], The virus has subsequently 
been found to be a common infection throughout the world and to
be a significant cause of disease in the cat [2,3,4]. FIV is
also emerging as an important model for human immunodeficiency 
virus (HIV) [1,5,6].
In this chapter the properties of the retroviruses and especially 
the lentiviruses will be described. As interest in the animal 
lentiviruses has increased considerably since the isolation of 
the human lentivirus, each of the lentiviruses will be described. 
The aspects which will be reviewed are the epidemiology of the
infections, the clinical signs of the diseases, the diagnosis of 
the infections, the cell tropisms of the viruses (both in vivo 
and in vitro) and studies towards vaccination.
1.1. RETROVIRIDAE
The Retroviridae family includes all viruses containing an RNA
genome and an RNA-dependent DNA polymerase (reverse 
transcriptase) enzymatic activity [7]. All retroviruses have 
common morphological, biochemical and physical properties that 
justify their inclusion into a single virus family. These 
properties are shown in table 1.1. A detailed description is
15
Table 1.1
Taxonomic features of Retroviridae
Nucleic acid
Protein
Lipid
Carbohydrate
Density
Morphology
linear, positive-sense single-stranded RNA 
methylated cap structure at 5' end 
polyadenylate tract at 3' end 
contains 3 genes encoding structural proteins:
5'-gag-£ol-eny-3'
approx. 60% by weight;
gag: internal structural proteins 
pol: reverse transcriptase 
env: envelope proteins
approx. 35% by weight; derived from cell membrane
approx. 4% by weight; associated with env proteins
1.16-1.18 gml“* in sucrose
spherical enveloped virions (80-120 nm diameter) 
variable surface projections 
icosahedral capsid
ribonucleoprotein complex with a core shell
given by Weiss et al [8]. The family is divided into 3
subfamilies:
i. Oncovirinae
This subfamily includes the oncogenic and closely related non- 
oncogenic viruses. There are 4 distinct subgroups: type-A, type- 
B, type-C and type-D viruses. The oncoviruses of human and 
veterinary importance are C-type and are exogenous, being spread 
either by contact or congenitally. There are also many endogenous 
oncoviruses which do not normally occur in an infectious form. 
These viruses exist in cellular DNA as proviruses and are
transmitted genetically. They may be entirely latent, partially 
expressed or some may be spontaneously activated and cause 
disease.
ii. Lentivirinae
Lentiviruses establish persistent infections and 
characteristically cause chronic, slowly progressive diseases. 
The members of the group are human immunodeficiency virus (HIV), 
simian immunodeficiency virus (SIV), feline immunodeficiency 
virus (FIV), visna virus (VV), caprine arthritis encephalitis
virus (CAEV), equine infectious anaemia virus (EIAV) and bovine
immunodeficiency virus (BIV).
ii. Spumavirinae
Spumaviruses are the "foamy" viruses which establish persistent 
infections in several species but are generally considered 
apathogenic. They may contaminate primary cell cultures and cause 
intense vacuolation of the cell cytoplasm and very marked 
syncytium formation.
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1.2. LENTIVIRINAE
1.2.1. Morphology
Lentiviruses are typically 100-150nm in diameter with a bar or 
cone shaped core. The virus particles bud from cell membranes and 
the envelope has short spikes which can be seen on the cell 
surface but which are lost on budding.
1.2.2. Genetic Organisation
The genome of lentiviruses is a positive-stranded polyadenylated 
RNA of 9 to 10 kilobases. Although the structure and function of 
the viral genes has been studied most extensively for HIV-1, it 
is likely that all lentiviruses are similar. Figure 1.1 shows the 
genetic organisation of HIV-1. The genome contains three genes 
(gag, gol and env) which are common to all retroviruses. The 
genome is flanked by long terminal repeats (LTRs) which do not 
code for any protein but contain regulatory elements. In 
addition, lentiviruses have unique open reading frames (ORFs) 3' 
to the gql gene which have regulatory functions. Whereas other 
retroviruses require dividing cells, lentiviruses require 
activation and/or differentiation of the host cell for productive 
replication. These additional ORFs probably account for the 
ability of lentiviruses to replicate in non-dividing, end-stage 
cells by providing either additional virus-encoded replication 
functions or by activating the non-dividing cells to synthesise 
proteins and other factors necessary for DNA replication and 
integration.
In HIV, the gag-gol region is transcribed in a single genome 
length mRNA from which 2 proteins are translated: the gag
precursor (p55) and a gag-pol fusion protein of Mr 160 x 10^. The 
gag gene product, p55, is cleaved to the 3 core proteins, the 
matrix protein pl8 (MA), the capsid protein p24 (CA) and the 
nucleocapsid protein pl3 (NC). The gol gene encodes the enzymes 
reverse transcriptase (RT), endonuclease (EN) and integrase (IN).
17
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The env gene encodes a large polyprotein of Mr 100 x 10^ which 
becomes glycosylated to give the envelope precursor gpl60. The 
precursor is cleaved to give the surface glycoprotein gpl20 (SU) 
and the transmembrane protein gp41 (TM). The only notable 
antigenic cross-reactivities and nucleic acid sequence homologies 
among lentiviruses have been demonstrated for the gag and pol 
genes.
The regulatory genes are tat, rev, vrf, nef, vgr and vgu (Figure 
1.1). In HIV-2 and SIV there is an additional gene, vgx. The tat 
gene codes for a transactivator of viral gene expression which 
binds the transactivator receptor (TAR) element in the R region 
of the LTR and thereby promotes the expression of other viral 
proteins. The products of both tat and rev are necessary for 
viral protein synthesis and the vvf protein is necessary for the 
production of fully infectious virus particles. The nef product 
is thought to reduce virus expression. The functions of vpr, vgu 
and vgx are unknown.
At both the 5' and 3' LTRs are sequences containing the cap site, 
the polyadenylation signal and the termination signal for viral 
transcription (R region). Sequences at the 5' LTR in the U3 
region contain the enhancer-promoter elements for initiation of 
RNA transcription. The primer binding site for the synthesis of 
minus strand viral DNA is immediately downstream of the U5 region 
and for the plus strand is immediately upstream of the U3 region.
1.2.3. Replication
Whereas other retroviruses synthesise proviral DNA in the 
cytoplasm, lentiviruses replicate in the nucleus, the site of 
cellular DNA synthesis. Also, in contrast to other retroviruses, 
lentivirus-infected cells contain only a small proportion of 
circularised DNA and little integrated DNA. There are large 
amounts of unintegrated, linear DNA in the nucleus of the 
infected cell which may be associated with cytopathogenicity [9].
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The mechanism of control of latency in lentiviral infections is 
not known but it has been shown that signals which can activate 
cell division and differentiation may lead to proviral expression 
and the release of large amounts of infectious virus, causing the 
cell lysis which is typical of lentiviruses [10].
1.3. REVIEW OF LENTIVIRUS LITERATURE
1.3.1. Human immunodeficiency virus
The acquired immunodeficiency syndrome (AIDS) was first described 
in 1981 when cases of Pneumocystis carinii pneumonia (PCP) and 
Kaposi's sarcoma (KS) were seen in previously healthy young male 
homosexuals. The syndrome was soon found in other groups, 
including intravenous drug users, recent Haitian immigrants, 
haemophiliacs, recipients of blood transfusions, sexual partners 
of individuals either having or at risk of having the disease and 
offspring of mothers with or at risk of the disease. In 1983- 
1984, researchers in France and the United States independently 
identified the cause of AIDS. Termed lymphadenopathy-associated 
virus (LAV) [11], human T cell lymphotropic virus-III (HTLV-III) 
[12] and the AIDS associated retrovirus (ARV) [13], the virus was 
renamed human immunodeficiency virus (HIV) in 1986 [14].
There are two distinct serotypes of HIV, HIV-1 and HIV-2. Whereas 
HIV-1 is primarily found in Central Africa, Europe and the United 
States, HIV-2 has mainly infected individuals in countries in 
West Africa. HIV-2 has a similar ultrastructure and demonstrates 
the same cell tropism as HIV-1, but the overall nucleotide 
sequence homology between the two serotypes is only 42% [15].
Indeed HIV-2 shows greater sequence homology to the simian 
immunodeficiency virus (SIVmac) which was isolated from captive 
rhesus macaques. SIVagm was isolated from wild African Green 
monkeys and is approximately equally related to HIV-1 and HIV-2 
[16]. A virus (SIVCpZ ) isolated from a chimpanzee in Gabon has 
been shown to be closely related to HIV-1 [17].
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1.3.1.1. Epidemiology
The infection is worldwide and it is estimated that 1 to 2 
million people in the United States and 5 to 10 million in Africa 
and other countries are infected with HIV [18]. It appears that 
the majority of people infected with HIV will eventually develop 
AIDS.
HIV is transmitted by direct contact of genital or rectal mucosa 
with infected semen or vaginal secretions, by direct inoculation 
of contaminated blood or by perinatal infection. Extensive 
evidence suggests that the virus is rarely, if ever, transmitted 
via sneezing, coughing, contact with skin or oral mucosal 
membranes or by insect vectors [18].
There are 3 epidemiological patterns [19]. The first pattern 
arises from heterosexual transmission and occurs in Africa, the 
Caribbean and parts of South America. In these areas there is an 
equal prevalence in males and females and the major risk factor 
is the number of sexual partners. Perinatal and parenteral 
transmission via contaminated blood are also important routes of 
infection. The second pattern of transmission arises where 
homosexual transmission occurs and where there is intravenous 
drug use. In this situation the major risk factors are male 
homosexuality, intravenous drug use, blood transfusion and 
haemophilia. The third pattern is seen in areas where HIV has 
been recently introduced, such as Asia, and the Middle East. In 
these areas the incidence of infection is low and the rate of 
spread will depend on the prevalent social habits.
1.3.1.2. Clinical Signs
The clinical manifestations of AIDS are reviewed by Volberding 
and McCutchan [18]. After infection with HIV, there is an 
assymptomatic phase lasting 5 to 10 years. A minority of infected 
individuals will develop AIDS within 1 to 5 years. Shortly after 
infection there may be an influenza-like illness lasting 3 to 14
20
days. There may be fever, lethargy, lymphadenopathy and other 
non-specific signs. The lymphadenopathy may persist. As the 
immune system becomes increasingly impaired, syndromes such as 
oral candidiasis, herpes zoster and oral hairy leukoplasia may 
appear and resolve. The clinical forms of AIDS vary depending on 
risk group and region. KS is more common in homosexual men 
compared to haemophiliacs and PCP is more common in recipients of 
blood transfusions compared to homosexuals. Toxoplasmosis is more 
common in Europe than in the United States and tuberculosis and 
cryptococcal meningitis are more common in Africa.
1.3.1.3. Diagnosis
Infection is diagnosed by the demonstration of antibodies or, 
less commonly, antigen in the blood. Serum antibody is detected 
by ELISA and positive samples are confirmed by immunoblotting. 
Antibodies may be detected between 2 weeks and 3 months after 
infection [20]. The antigen tests for p24 are useful in early 
infection, before antibodies have developed, and in rare 
individuals who do not develop antibodies.
1.3.1.4. Cell tropism
Infected haematopoietic cells are the most frequent source of 
infectious virus in infected individuals [21]. HIV has been 
detected in lymphocytes, macrophages, follicular dendritic cells 
and megakaryocytes. To recover HIV, the optimal culture procedure 
involves co-cultivation of the cells or tissue with mitogen- 
stimulated peripheral blood mononuclear cells from normal donors, 
propagated in medium containing interleukin-2 (IL-2).
The in vivo depletion of CD4+ helper T-cells in HIV-infected 
individuals [22] and the in vitro tropism of HIV for cells 
bearing the CD4+ surface antigen [23] suggested that the receptor 
for HIV was CD4. HIV infects T-cells via an interaction between 
the envelope protein gpl20 and CD4. This interaction can be 
blocked by monoclonal antibodies against CD4 [23,24,] and by
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recombinant soluble CD4 [25,26]. Human monocytes and macrophages 
also express CD4 and can be infected with HIV, possibly becoming 
the main reservoir of infection and transporting the virus to 
various organs, including the brain.
Since a number of CD4- cells have been shown to be infected in 
vitro, it is possible that alternative receptors for HIV exist. 
McKeating et al [27] demonstrated that HIV can infect CD4- cells 
via Fc receptors when complexed with low levels of antibody. Fc 
receptors on macrophages have been implicated in enhancement of 
HIV infection.
1.3.1.5. Vaccination
Chimpanzees have been protected from infection by HIV-1 after 
vaccination with recombinant gp!20, showing no signs of infection 
after more than 6 months [28]. The immunogen was prepared in an 
aluminium hydroxide adjuvant and inoculated at 0, 1 and 8 months. 
Significant levels of neutralising antibodies were achieved. The 
animals were challenged at week 35 with 10 infectious units of 
homologous virus.
1.3.2. Simian immunodeficiency virus
SIV was first isolated from captive rhesus macaque monkeys, 
Macaca mulatta (SIVmac) [29]. Subsequently, many isolates of SIV 
have been obtained from a variety of species of captive and wild 
monkeys, including sooty mangabey monkeys, Cercocebus atvs 
(SIVsm) , pig-tailed macaques, Macaca nemestrina (SIVmne),  
cynomolgus monkeys, Macaca fascicul aris and African green 
monkeys, Cercopithecus aethiops (SIVagm).  With the exception of 
SIVagm isolates, which have not been tested extensively, 
experimental infection of macaques with other SIV isolates 
results in immunosuppressive disease similar to the disease 
associated with HIV infection.
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1.3.2.1. Epidemiology
Antibodies to SIV were found in 26-42% of sera from wild African 
green monkeys from east Africa [30,31] although there is no 
evidence of disease in SIV-infected African green monkeys. The 
prevalence of the infection and the routes of transmission in the 
wild are unknown. In colonies of captive monkeys where SIV is 
enzootic, prenatal and contact transmission occur.
None of the SIV strains characterised so far are closely related 
to HIV-1. HIV-2, on the other hand, is closely related to SIVmac 
and SIVsmm. SIVagm is eqidistant between HIV-1 and HIV-2 [32]. As 
Asian macaques are not infected with SIV in the wild, captive 
macaques probaly acquired SIV by cross-species transmission from 
an SIV-infected African primate in a primate centre. This 
hypothesis is supported by both molecular and epidemiological 
data [32]. The unusually close relationship between SIV from 
captive macaques with HIV-2 has led to the suggestion that 
primates in captivity became infected from a human being with 
HIV-2 infection (Dr Hayami, personal communication).
1.3.2.2. Clinical signs
The clinical signs seen in experimentally infected macaques are 
similar to those of HIV infection. There is a relatively short 
acute phase with viraemia, the level of which decreases as the 
antibody titre increases. There is an asymptomatic phase which 
may include sporadic episodes of disease and this is followed, 
after a variable period, by chronic progressive signs and death 
from immunosuppression and opportunistic infections. A detailed 
description of the clinical manifestations and pathology of SIV 
infection is given by Fultz and Anderson [33].
1.3.2.3. Diagnosis
SIV is diagnosed by the presence of antibody using ELISA, 
immunoblotting or neutralisation tests. Virus can be isolated by
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co-cultivation of peripheral blood T-cells with human T-cells and 
virus can be identified by immunofluorescence, electron 
microscopy or reverse transcriptase assay of culture fluids.
1.3.2.4. Cell tropism
Studies to assess the cellular tropism of various SIV isolates 
have identified some differences as well as similarities between 
HIV and SIV. While both viruses are tropic for CD4+ lymphocytes 
and macrophages, in vitro replication of at least some SIV 
strains in human CD4+ cells is more restricted than HIV. It 
appears that in addition to binding CD4, another molecule is 
required for virus entry into cells [34].
1.3.2.5. Vaccination
Several groups have demonstrated that vaccines derived from whole 
virus can induce immune responses that protect against infection 
[35,36,37].
1.3.3 Feline immunodeficiency virus
FIV is the most recently discovered lentivirus and is associated 
with immunosuppression in domestic cats. Like the human and 
simian lentiviruses, FIV is T-lymphotropic, persists in infected 
animals and causes severe immunodeficiency in the natural host 
[1]. There is a significant degree of genetic relatedness between 
FIV and other lentiviruses, especially in the gag-£ol genes [5] 
and common antigenic determinants are shared by the major core 
proteins of FIV, CAEV and VV [5]. The organisation of its small 
ORFs is most similar to that of VV, although the cell tropism and 
pathogenesis of FIV infection are most similar to those of HIV 
and SIV.
1.3.3.1. Epidemiology
FIV has been detected wherever attempts have been made to
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identify infected cats. Several serological surveys have reported 
similar findings for the prevalence of infection in the USA, the 
UK and France; 10 to 19% of sick cats and 1 to 6% of healthy cats 
[4,38,39,40,41]. The prevalence was shown to be markedly higher 
in Japan [2] and very low in the Netherlands, Germany and 
Switzerland [38,42]. Male cats are more commonly infected than 
female cats and transmission occurs by biting.
1.3.3.2. Clinical signs
After experimental infection with FIV, kittens develop pyrexia 
which lasts a few days, neutropaenia which lasts a few weeks and 
lymphadenopathy which persists for several months [3]. Animals 
appear normal after this primary phase but following a long 
latent period, cats develop signs of immunodeficiency.
The most common clinical signs are lethargy, anorexia, weight 
loss, pyrexia and lymphadenopathy [43]. Other common signs are 
gingivitis, diarrhoea and rhinitis [4,43,44]. Neurological 
deficits may occur [45]. A significant correlation has been 
found between FIV infection and lymphoproliterative malignancies 
[46]. Opportunistic infections such as T o x o p Iasma gondii and 
Demodi cos is have been reported [47,48]. Pre-existing infection 
with FeLV potentiates the severity of the transient primary and 
chronic secondary stages of FIV infection [49].
1.3.3.3. Diagnosis
Diagnosis of infected animals is by demonstration of antibodies 
by ELISA or immunoblotting [1,2,3,6,50]. Virus can be isolated 
from the peripheral blood T-cells of infected cats [1,51].
1.3.3.4. Cell tropism
Like HIV and SIV, FIV is T-lymphotropic. Macrophages can be 
infected in vivo and in vitro [52]. Some molecular clones infect 
feline fibroblasts in vitro but replicate less efficiently on
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feline peripheral blood T-cells [53].
1.3.3.5. Vaccination
Preliminary vaccine trials have shown that inoculation with 
inactivated FIV-infected cells or purified virus will protect 
cats from infection [54].
1.3.4. Visna virus
Visna virus was the first lentivirus to be isolated and
characterised. The virus may also be called maedi virus or maedi- 
visna virus. The virus is associated with a pneumo-encephalitic 
disease complex (maedi, laboured breathing: visna. paralysis and 
wasting, in Icelandic) which occurred in epidemic form in Iceland 
following the introduction of latently infected sheep from Europe 
during the 1930s.
1.3.4.1. Epidemiology
The infection is found in sheep throughout the world except
in Australia or New Zealand. The prevalence of the disease is
low, although certain breeds (such as Border Leicester sheep in
the USA and Texel sheep in the Netherlands) seem to be more 
susceptible. The virus is transmitted primarily in milk although 
direct transmission may occur, especially where there is 
overcrowding. In infected flocks the prevalence increases with 
age, from 20% in year-old lambs to 80% in animals older than 7 
years. In the majority of sheep, infection is asymptomatic [10].
1.3.4.2. Clinical signs
The main clinical feature is a chronic progressive interstitial 
pneumonia (maedi) with lymphoid hyperplasia. The pneumonic form 
is more common than the neurological form (visna) which was once 
common in Iceland, causing paralysis due to a severe 
meningoencephalitis, often with demyelination. Many infected
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sheep also have an indurative mastitis.
1.3.4.3. Diagnosis
Diagnosis of infected animals is by demonstration of antibodies 
by immunodiffusion or ELISA.
1.3.4.5. Cell tropism
The monocyte/macrophage is the principal target for viral 
replication. The virus is latent in monocytes and becomes 
activated with cell differentiation. There is a persistent, cell- 
associated viraemia by which virus spreads to many other organs.
1.3.4.5. Vaccination
Attempts have been made to vaccinate sheep using whole virus 
inactivated by UV irradiation as well as envelope glycoprotein 
gpl35 concentrated from cell culture supernatant and purified on 
lectin columns [55]. On challenge with live virus by the 
respiratory route there was no protection.
1.3.5. Caprine arthritis encephalitis virus
A close relationship exists between the visna virus of sheep and 
the CAEV. Persistently infected goats are common but disease is 
rare.
1.3.5.1. Epidemiology
CAEV occurs worldwide. Transmission studies have shown that 
infection usually occurs via colostrum or milk and rarely by 
direct contact [56]. Age does not appear to play a role in 
susceptibility.
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1.3.5.2. Clinical signs
The most common clinical sign is chronic arthritis, often 
accompanied by bursitis. Virus is expressed in the synovial 
membranes of the joints soon after experimental infection and can 
be isolated from synovial membrane biopsies of clinical cases. 
Neurological signs may occur, especially in young kids, with foci 
of inflammatory cells and demyelination throughout the white 
matter of the brain and spinal cord. Other signs which can be 
associated with infection are pneumonia, mastitis, interstitial 
nephritis, myocarditis and hyperplasia of the lymphoid tissues 
[56].
1.3.5.3. Diagnosis
Diagnosis of infected animals is by demonstration of antibodies 
by immunodiffusion or ELISA. Antibody titres are higher to gpl35 
than to p28 and therefore tests which use gpl35 as antigen are 
preferable [57].
1.3.5.4. Cell tropism
As in VV infection, the main target cell for CAEV is the 
monocyte. In vitro, the virus will grow in cells from choroid 
plexus, foetal testicle, cornea, synovial membrane and in a 
permanent cell line from a Himalayan tahr ovary [56].
1.3.6. Equine infectious anaemia virus
1.3.6.1. Epidemiology
EIAV occurs in south-eastern USA, south and central America, 
southern Africa and northern Australia. The virus is transmitted 
mechanically from viraemic horses by biting flies (Stomoxvs 
spp.), mosquitos, midges and iatrogenically via unsterilised 
hypodermic needles.
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1.3.6.2. Clinical signs
The clinical signs of EIAV have been reviewed by Narayan and 
Clements [10]. The disease may occur as an acute syndrome which 
is fatal within one month of infection or as a chronic relapsing 
disease causing cachexia and chronic anaemia. Some infected 
animals, however, never develop the disease but act as carriers 
of the virus. After infection, horses develop fever, anorexia and 
anaemia which lasts a few days and is followed by a period of 
clinical normality which may last for weeks or months. There are 
three or four cyclical recrudescences of the disease before the 
onset of chronic wasting. Some animals remain clinically normal 
although stress or the administration of corticosteroids may 
cause an episode of disease. Acute disease is characterised by 
haemolytic anaemia and haemorrhages and necrosis of hepatocytes 
and lymphocytes in the spleen and lymphatic tissues [58].
The disease is immune-mediated, the anaemia resulting from 
complement-dependent lysis of erythrocytes which have become 
coated in viral antigen and the pyrexia resulting from 
circulating immune complexes containing EIAV. Glomerulonephritis 
is also common as a result of the deposition of immune complexes 
in the kidney. The periodic onset of disease is associated with 
the appearance of new antigenic variants, followed by a period 
when the virus is latent, probably as a result of specific 
neutralising antibody.
1.3.6.3. Diagnosis
Diagnosis of infected animals is by demonstration of antibodies 
by immunodiffusion or ELISA.
1.3.6.4. Cell tropism
In the infected animal, EIAV primarily infects and destroys 
peripheral and tissue macrophages. In vitro, EIAV can be 
propagated in equine peripheral blood mononuclear cells and can
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be adapted to grow in foetal equine kidney and foetal donkey 
dermal cells [59].
1.3.6.5. Vaccination
Vaccination using formal in-inactivated EIAV in muramyl dipeptide 
induced neutralising antibodies. After challenge, 9 of 12 ponies 
were shown to be carriers of EIAV but none had clinical signs and 
therefore vaccination prevented disease [60],
1.3.7. Bovine immunodeficiency virus
The bovine lentivirus was first described by Van Der Maaten et al 
[61]. There has been little research of the pathogenesis, host 
immune response or epidemiology of BIV infection of cattle.
1.3.7.1. Epidemiology
Preliminary seroepidemiological studies suggest that BIV is 
sporadically present in dairy cattle in the USA [62]. Virus may 
be transmitted iatrogenically via unsterilised hypodermic 
needles.
1.3.7.2. Clinical signs
Cattle infected with BIV have signs of lymphadenopathy, 
lymphocytosis, central nervous system lesions, progressive 
weakness and emaciation [10].
1.3.7.3. Diagnosis
Diagnosis of infected animals is by demonstration of antibodies 
by immunofluorescence or immunoblotting [63].
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2. MATERIALS AND METHODS
2.1. MATERIALS
2.1.1. Cells
Normal feline T-cells were isolated from peripheral blood as 
described in section 2.2.2. and normal cat thymocytes were 
isolated as described in section 2.2.3. These cells could be 
maintained in culture containing recombinant human IL-2 for many 
months.
Q201 cells were antigen-specific T-cells against ovalbumin. A cat 
was immunised three times with ovalbumin ISCOMs. Each 
inoculation was given at 4 weekly intervals and contained lmg 
ovalbumin and 50ug Quil A (Oswald Jarrett, personal 
communication). Two weeks after the third inoculation, peripheral 
blood T-cells were isolated using the method described in section
2.2.2. The cells were cultured with autologous antigen presenting 
cells in the presence of 50ug per ml ovalbumin. The culture was 
incubated for 4 days and re-cultured for a week without antigen 
but in the presence of IL-2. Further antigen presentations were 
made at monthly intervals for 4 months after which the cells were 
seen to proliferate without further antigen presentations. Q201 
cells remained IL-2 dependent. P51 cells were developed using 
similar methods as for Q201 cells but in this case the antigen 
was FeLV rather than ovalbumin (Angela Pacitti, personal 
communication). P51 cells were shown to produce small amounts of 
FeLV (Angela Pacitti, Oswald Oarrett and Helen Laird, personal 
communications).
3201 is an FeLV nonproducer line established from a naturally 
occuring feline lymphosarcoma [64]. FL74 is also a permanent 
feline lymphoblastoid cell line derived from a lymphosarcoma but 
is productively infected with FeLV [65]. F422 was established 
from a thymic lymphosarcoma of a kitten inoculated with the 
second passage of the Rickard strain of FeLV [66]. F422-MD cells
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are a variant producing non-infectious FeLV (Oswald Jarrett, 
personal communication). T3 was derived from an FeLV-positive 
feline thymic lymphosarcoma with m^c-containing proviruses [67]. 
McCoy cells were derived from a neoplastic feline mesenteric
lymph node [68] and are negative for FeLV.
Crandell feline kidney cells (CRFK) were derived from the renal 
cortical cells of a normal domestic kitten [69]. A clone of CRFK, 
designated ID10 (kindly provided by P Andersen), had been shown 
to support the growth of the Petaluma strain of FIV. The ID10 
cells were transfected with ras and myc genes to give the H06TI 
and MCGM1 lines, respectively (kindly provided by D Spandidos). 
AH927 cells were derived from a feline embryo culture which
underwent spontaneous transformation [70].
2.1.2. Experimental Cats
The experimental cats were obtained from the specific pathogen 
free cat colony of the University of Glasgow Department of 
Veterinary Pathology. The cats were bred within the colony and 
were in housed in small groups. The cats used in the the present 
studies were randomised according to age and sex before being 
assigned to the experimental and control groups.
2.2. METHODS
2.2.1. Cell Culture
q o q
Cells were routinely grown in 25cm , 80cm° or 175cnr plastic
flasks in an atmosphere of 5% CO2 in air and were incubated at 
37°C. All cells were cultured in RPMI-1640 (Gibco, UK) with 10% 
foetal bovine serum (Imperial laboratories, UK), 2mM glutamine 
(Gibco, UK), 100 units penicillin per ml (Gibco, UK), lOug 
streptomycin per ml (Gibco, UK) and 2 x 10"^ moles per ml 2- 
mercaptoethanol (Sigma). This medium was supplemented with 100 
units per ml recombinant human IL-2 (kindly provided by Jack 
Nunberg, Cetus Corporation) for peripheral blood T-cells,
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thymocytes, Q201 and P51 cells.
Suspension cells (T-cells, thymocytes, Q201, P51, 3201, FL74,
F422, T3 and McCoy) were grown at a concentration of between 5 x 
105 and 1.5 x 10^ cells per ml. They were subcultured every 3 to 
4 days. On occasions where there was a high percentage of dead 
cells, Ficoll-Hypaque solution (Pharmacia, Sweden) was used to 
remove these cells from the culture. A volume of 10mls of 
suspension culture was gently layered on top of lOmls Ficoll- 
Hypaque in a 25ml centrifuge tube and was spun at 2000rpm for 10 
minutes. The live cells, which collected in a band at the 
interface, were removed and diluted to 20mls in RPMI-1640 and 
spun again at lOOOrpm for 5 minutes. The cell pellet was then 
resuspended at the appropriate density in culture medium.
Monolayer cells (ID10, H06TI, MCGM1 and AH927) were subcultured 
at a ratio of 1:4 twice weekly. The culture fluid was removed and 
the adherent cell monolayers were dispersed by rinsing twice in a 
solution of 0.01% trypsin and 0.02% EDTA in RPMI-1640. The cells 
were diluted with culture medium, centrifuged at lOOOrpm for 5 
minutes and resuspended in fresh culture medium.
2.2.2. Isolation of peripheral blood T-cells
T-cells were isolated from 2 to 20mls heparinised blood using the 
Ficoll-Hypaque method. The heparinised blood sample was diluted 
in 3 times its volume of RPMI-1640 and transferred carefully as 
an overlay to a 25ml centrifuge tube containing 10mls Ficoll- 
Hypaque solution (smaller tubes were used when only small samples 
were available). The blood was centrifuged at 2000rpm for 10 
minutes with the brake switched off to minimise swirling. The 
pellet contained erythrocytes and granulocytes and the interface 
contained the mononuclear cells. The interface was aspirated and 
transferred to a clean tube, diluted with at least a 5-fold 
excess of medium, mixed and centrifuged at lOOOrpm for 5 minutes 
to pellet the peripheral blood mononuclear cells. The cells were 
resuspended in medium at a cell concentration of 5 x 10^ cells
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per ml and the peripheral blood T-cells were stimulated to grow 
by the addition of 7.5ug per ml Concanavalin A (Con A) (Sigma, 
UK). After 2 or 3 days in Con A, the unattached cells were 
collected by centrifugation and were resuspended in a new flask 
in medium without the addition of Con A.
2.2.3. Isolation of Thymocytes
To prepare a culture of thymocytes, the thymus from a normal 
kitten was taken aseptically into RPMI-1640. The tissue was 
placed in a petri dish and was teased aseptically using forceps 
and a scalpel to expel the cells. When the fragments of tissue 
could be broken no further, the thymocytes were resuspended in 
culture medium and centrifuged at lOOOrpm for 5 minutes. The cell 
pellet was resuspended in 10mls medium and and aspirated with a 
pipette to distribute the cells evenly. Any clumps which would 
not disperse were discarded. The thymocytes were washed twice and 
resuspended in normal T-cell medium containing Con A. After 3 
days the thymocytes were cultured in medium without Con A.
2.2.4. Growth of FIV-Glasgow-8 (FIV-8)
The isolation of FIV-8 is described in chapter 5. The virus was 
grown in cat peripheral blood T-cells (PBTs). Approximately 6 x 
10^ PBTs were resuspended in FIV-8-infected supernatant 
overnight. Five days later the medium was changed and the same 
volume of uninfected PBTs was added to the culture. Three days 
later the medium was again changed and uninfected cells were 
added at a ratio of 5 to 1. This was repeated 4 days later. The 
supernatant collected each time the medium was changed was 
filtered through a 0.45um filter and frozen at -70°C.
2.2.5. Production of FIV-8 stock
FIV-8 was grown in normal cat thymocytes. Uninfected thymocytes 
were incubated overnight with 50 mis of FIV-8-infected tissue 
culture supernatant at a concentration of 2 x 10^ cells per ml.
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The following day the cells were washed and the concentration of 
cells was adjusted to 5 x 10^ cells per ml. The culture was 
monitored for cytopathic effect and when this was evident (5 days 
post-infection), the cell suspension was centrifuged at lOOOrpm 
for 5 mins and the supernatant was filtered through a 0.45 urn 
filter and frozen in 1ml volumes at -70°C. Assay of virus 
infectivity in P51 cells showed the virus titre to be 10^.
2.2.6. Detection of Viral Antigen
FIV p24 antigen in tissue culture supernatants was detected using 
a monoclonal antibody based enzyme-linked immunosorbent assay 
(ELISA) kit (FIV antigen detection kit, Idexx) which had a 
sensitivity limit of 0.2ng per ml [71].
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3. EPIDEMIOLOGICAL SURVEY
3.1. INTRODUCTION
The primary aim of this survey was to assess the prevalence of 
FIV in the UK and to compare this with the prevalence of FeLV. 
The survey was designed to be representative of the whole feline 
population. The data for each infection were examined for 
evidence of any associations between prevalence and disease 
status, sex, age and breed in order to identify those groups most 
likely to be infected. Data from multi-cat households were 
analysed to assess the relative transmissibility of each virus. 
The clinical signs which could be associated with each infection 
were examined.
3.2. MATERIALS AND METHODS
3.2.1. Blood samples
Blood samples were taken into heparin although occasionally 
clotted blood was used. Heparinised blood or serum was 
centrifuged at 2000 rpm for 10 minutes and the fluid was 
separated. Plasma and serum samples were stored at -80 °C. 
Repeated freezing and thawing of samples was avoided; the 
majority of samples were tested for both viruses before storage 
and the remainder were frozen and thawed once prior to testing.
i.Sick cats
The samples from cats showing clinical signs were submitted to 
the Feline Virus Unit (FVU) diagnostic laboratory at the 
University of Glasgow by veterinary practitioners throughout the 
UK. These samples were from cats of all ages and breeds, in which 
clinical signs had been observed which may have been associated 
with FeLV or FIV infection.
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ii.Heal thy cats
The samples from cats without clinical signs were from two 
sources. The FVU laboratory routinely received samples from cats 
as part of a pre-breeding screening programme for FeLV , as well 
as from healthy cats which may have been exposed to other cats 
infected with FeLV. This population consisted predominantly of 
young pedigree cats. In order to obtain samples from healthy non­
pedigree cats, veterinary practitioners throughout the UK were 
requested to submit samples from any healthy cats which were 
presented for elective surgery, such as castration or spaying, 
orthopaedic operations, de-matting procedures or as a result of 
road traffic accidents.
3.2.2. Diagnostic tests
A commercial ELISA (PetChek feline T lymphotropic lentivirus 
antibody test kit, Idexx) was used to detect antibodies against 
FIV. Samples were screened for FeLV antigen using an ELISA to 
detect p27 antigen and positive results were confirmed by virus 
isolation [72].
3.3.3. Database
A computer database was constructed to record the details of each 
cat tested. The data covering health status, age, sex, and breed 
were complete for 2211 cats. Any clinical signs which were given 
on the submission form were noted for the sick cats and the 
reason for consultation was noted for the healthy cats. This 
information could be related to the results of the FIV and FeLV 
tests. Only single submissions were included in this analysis.
In the database 1190 cats belonged to multi-cat households, 205 
were from single cat households and the remainder were from 
households with unknown numbers of cats. There were 72 multi-cat 
households, containing 301 cats, in which at least one cat was 
FIV-positive and 28 households, containing 137 cats, in which 
FeLV was present.
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3.3.4. Statistical analysis
Four factors were considered in the analysis of the prevalence of 
FIV and FeLV, namely health status, age, sex and breed. Health 
status was recorded as either sick (if clinical signs were 
present) or healthy (if there were no clinical signs). Cats which 
were sampled while undergoing dental procedures were excluded 
from the analysis as gingivitis may have been present in these 
cases. Therefore these cats could not faithfully be categorised 
as healthy. Cats were divided into four groups by their age at 
the time of sampling, the first being less than or equal to 1
year of age, the second being less than or equal to 5 years of
age and over 1 year, the third being less than or equal to 10 
years of age and over 5 years and the final group of cats which 
were over 10 years of age. The sex was recorded as entire male, 
neutered male, entire female or neutered female. For the 
analysis, the breeds were classified into two groups. The 
domestic cats comprised domestic shorthaired and domestic 
longhaired cats and all of the pedigree cats were analysed as one 
group.
The analyses of the prevalence of both FIV and FeLV was by log- 
linear modelling [73]. The four factors of health status, age, 
sex and breed which were considered in the analyses gave rise to 
64 combinations. For each combination, the proportion of cats 
which was positive in each test was recorded. Unlike a comparison 
of percentages, which are calculated ignoring the other factors, 
the model gave parameter estimates which controlled for the other 
factors. The parameter estimates were kindly calculated by C. 
Robertson. The more positive the value of the parameter estimate, 
the greater the likelihood of infection.Therefore it was possible
to determine which of the factors influenced the proportion of
positive cats, as well as the relative magnitude of their 
effects. The analyses also included the investigation of 
interactions between any two of the four factors.
The prevalence of the two viruses in in-contact cats in pedigree
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and domestic households were compared by Chi-squared analysis. 
The occurrence of clinical signs which, from previous reports, 
were believed to be associated with infection by each virus, was 
compared in infected and uninfected cats in the same way.
3.3 RESULTS
3.3.1. Prevalence of FIV and FeLV
A total of 2211 cats was included, comprising 1204 sick cats, 
together with 1007 healthy cats which represented a control 
population. Of the sick cats, 3% were positive for both FIV and 
FeLV, 15% were positive for FIV alone, 14% were positive for FeLV 
alone and 67% were negative for both FIV and FeLV. The 
percentages of infected cats were statistically significantly 
lower in the healthy cats. Of the healthy cats 0.5% were positive 
for both FIV and FeLV, 5% were positive for FIV alone, 4% were 
positive for FeLV alone and 90% were negative for both FIV and 
FeLV.
A different pattern emerged for the age distribution of FIV or 
FeLV infected sick cats (Figure 3.1). The peak of FIV infection 
was seen in cats between the ages of 5 and 10 years whereas the 
peak of FeLV infection was in cats between 1 and 5 years of age.
The percentages of FIV or FeLV infected healthy cats were much
lower for each age group (Figure 3.2).
Initially the data for FIV and FeLV were analysed separately, in 
order to examine associations between prevalence and health 
status, breed, age and sex. In addition, the data for FIV and 
FeLV were analysed together to determine whether or not the two 
viruses behaved independently.
3.3.2. FIV Analysis
The prevalence in sick cats was 19% compared to 6% in healthy
cats. All four of the factors analysed were found to have an
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Figure 3.1
Bar chart showing the age distribution of the percentages of sick 
cats which tested positive for FIV and FeLV
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Figure 3.2
Bar chart showing the age distribution of the percentages 
healthy cats which tested positive for FIV and FeLV
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effect on the likelihood of FIV infection. Health status was the 
most important, followed by age, breed and sex (Table 3.1).
The likelihood of FIV infection increased with age and then 
decreased in the oldest age group. There was a lower probability 
of infection among healthy cats and also among pedigree cats. 
Female cats had the lowest probability of FIV infection. Neutered 
cats had a probability of infection which was slightly lower than 
that of entire males. Neutering did not alter the likelihood of a 
male cat being FIV-positive, but neutered females had an 
increased likelihood relative to entire females.
Since four factors were examined, there were six possible two- 
factor interactions to be investigated. Of these, the only 
interaction was between age and sex (Table 3.2). For entire male 
cats there was a steep rise in prevalence with increasing age. 
The other three sexes also showed increasing prevalence with 
increasing age, but this was followed by a decrease in the oldest 
age group. This age-sex interaction could be simplified by 
comparing the prevalences at each age for male and female cats 
and for neutered and entire cats. When the interaction was 
examined for males and females, the main difference was that for 
male cats the prevalence increased more steeply, peaked at a 
higher level and decreased to a lesser extent in the oldest age 
group compared to female cats. When entire cats were compared to 
neutered cats, it was observed that whereas the prevalence in 
entire cats increased between each increasing age group, the 
neutered cats displayed a considerable decrease in prevalence in 
the oldest age group.
3.3.3. FeLV Analysis
The prevalence of FeLV viraemia in sick cats was 18%, compared to 
5% in healthy cats. The effect of sex on the proportion of cats 
which was FeLV-positive was not significant. There was a lower 
probability of infection with healthy cats and pedigree cats. The
40
Table 3.1
The prevalence of FIV and FeLV by percentages and parameter 
estimates obtained by log-linear modelling
parameter
no
tested %FIV+
FIV _ 
E(SE) %FeLV+
FeLV 
E (SE)
health status
sick 1204 18.6 0(-) 17.5 O(-)
healthy 1007 5.8 1 CO UO i—
i
cn 4.5 -1.45(.18)
age
0-1 509 2.8 O(-) 9.8 O(-)
1-5 987 9.3 1.16(.30) 13.0 .20(.18)
5-10 518 27.0 2.26(.29) 12.6 -. 12(.21)
>10 197 18.3 1.75(.33) 6.6 - .84(.33)
breed
domestic 1609 15.5 O(-) 14.2 O(-)
pedigree 602 5.5 -.89(.20) 4.7 -1.03(.21)
sex
M 663 15.4 O(-) 12.8 O(-)
MN 443 19.2 - .07(.17) 13.5 • .14(.19)
F 819 6.1
cn■—i
001 9.4 -.15(.17)
FN 286 15.7 -.22(.21) 11.9 -.16(.22)
* Parameter estimates - (E) derived from additive model with 
deviance 62.2 on 53df with the standard error (SE) in 
parenthesis. This model did not take the age-sex interaction into 
account.
^ Parameter estimates (E) derived from additive model with 
deviance 41.5 on 53 df with the standard error (SE) in 
parenthesis.
Table 3.2
Interaction of age and sex in the prevalence of FIV
age
(years) M
sex
MN F FN
0-1 E(SE)
%
o ( - )
1.7
.61(.93) 
3.8
.63(.70) 
2.8
1.13(.94) 
6.0
1-5 E(SE)
%
1.87(.61) 
10.7
1.77(.63) 
11.6
1.36(.63) 
5.6
2.01(.64) 
13.4
5-10 E(SE)
%
3.09(.61) 
32.3
3.22(.61) 
36.1
1.86(.64) 
11.3
2.93(.64) 
28.2
>10 E (SE)
%
3.38(.66) 
39.1
2.20(.70) 
16.7
1 .62(.73) 
10.9
1.47(.79) 
8.3
Parameter estimates (E) with standard deviations in parenthesis 
and percentages for the prevalence of FIV according to age and 
sex, showing the interaction between these two parameters. These 
estimates were derived from the additive model plus age by sex 
interaction with deviance 40.2 on 44 degrees of freedom
main effect of age was that cats in the the oldest age group were 
much less likely to be FeLV-positive than younger cats. The 
highest probability of infection was among cats between 1 and 5 
years of age.
3.3.4. Combined FIV and FeLV Analysis
The sick domestic cats made up 44% of the cats sampled and 87% of 
FIV+/FeLV+ cats were in this group. Therefore this group was 
analysed separately. Overall, 4% of the cats were FIV+/FeLV+ and 
64% were negative for both infections. Approximately equal 
proportions were positive for one infection but not the other. 
Thus 17% were FIV+/FeLV~ and 16% were FIV"/FeLV+ .
For the sick domestic cats there was no indication of any 
interaction between the presence or absence of the two viruses. 
Each appeared to behave independently. FeLV was commoner in 
younger cats than older cats, whereas FIV was more prevalent in 
older cats. Similarly, when all the data were investigated there 
was no interaction between FIV and FeLV.
3.3.5. FIV in multi-cat households
FIV infection was detected in 58 households with a total of 234 
domestic cats and 14 households with a total of 67 pedigree cats
(Table 3.3). Overall, 21% of cats in contact with FIV were
positive. This figure ranged from 3% to 67% in different
households. The prevalence of FIV in the in-contact cats was
significantly higher in domestic cat households (24%) compared to 
pedigree cat households (9%).
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Table 3.3
Prevalence of FIV antibodies in multi-cat households (MCH) in which 
FIV was present
size of 
MCH
2
3
4
5
7
8 
9
11
21
24
31
Domestic Cats Pedigree Cats
no. MCH no.FIV+/ no. MCH no.FIV+/ 
no. tested no. tested
25
12
11
3
1
1
2
1
1
1
34/50
16/36
18/44
5/15
2/7
3/8
4/18
4/11
6/21
9/24
8
2
1
2
9/16
2/6
1/4
4/10
3/31
totals 58 101/234 14 19/67
minus index cases 43/176 (24%) 5/53 (9%)
3.3.6. FeLV in multi-cat households
FeLV infection was detected in 20 households with a total of 84 
domestic cats and 8 households with a total of 53 pedigree cats 
(Table 3.4). Overall, the prevalence of FeLV in the in-contacts 
was 14%, ranging from 0% to 100%. The difference between the 
prevalences in domestic and pedigree households was not 
significant, being 16% and 11% respectively.
3.3.7. Clinical signs in infected cats
The clinical signs which the veterinary surgeons noted on the 
submission form were ranked in order of occurrence for both FIV- 
positive cats and for FeLV-positive cats (Table 3.5).
The clinical signs which, from previous reports, were thought to 
be associated with FIV infection are listed in Table 3.6 
[1,2,3,74,43]. Also listed are the clinical signs which might be 
expected with FeLV infection. Pyrexia, gingivitis/stomatitis and 
respiratory signs were noted in a significantly higher proportion 
of FIV-positive sick cats compared to FIV-negative sick cats 
(Table 3.6).
The clinical signs which were noted in a significantly higher
proportion of FeLV-positive sick cats compared to FeLV-negative 
sick cats were pyrexia and anaemia (Table 3.6).
3.4. DISCUSSION
The prevalence data were examined to identify those groups of
cats most likely to be infected with FIV and FeLV and to provide
an indication of whether the transmissibility of FIV was 
different from FeLV. This survey demonstrates that both FIV and 
FeLV are important agents causing significant disease in cats. 
The prevalence of FIV was 19% in sick cats and 6% in healthy
cats. Other serological surveys have reported similar findings
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Table 3.4
Prevalence of FeLV viraemia in multi-cat households (MCH) in which 
FeLV was present
size of Domestic Cats Pedigree Cats
MCH no. MCH no. FeLV+/ no. MCH no. FeLV+/
no. tested no. tested
2 15 19/30 3 3/6
3 3 5/9 2 2/6
5 2 6/10
21 1 1/21
24 1 5/24
31 1 2/31
totals 20 30/84 8 13/53
minus index cases - 10/64 (16%) 5/45 (11%)
Table 3.5
Clinical signs in FIV and FeLV-positive cats, ranked in order of
prevalence.
1. FIV 2.FeLV
clinical sign no. of clinical sign no. of
FIV+ cats FeLV+ cats
with this with this
sign sign
pyrexia 115 pyrexia 106
weight loss 94 anorexia 85
anorexia 80 weight loss 78
gingivitis/stomatitis 67 anaemia 77
lethargy 59 lethargy 64
respiratory signs 52 respiratory signs 39
anaemia 47 gingivitis/stomatitis 35
diarrhoea 30 lymphadenopathy 30
lymphadenopathy 25 diarrhoea 22
nervous signs 15 vomiting 13
skin infections 8 hepatomegaly 8
vomiting 6 conjunctivitis 6
conjunctiviti s 6 nervous signs 6
jaundice 5 jaundice 5
neutropaeni a 5 thymic neoplasia 3
polyphagia 2 neutropaenia 4
haematuri a 2 polyphagia 2
splenomegaly 2 splenomegaly 2
hepatomegaly 1 ascites 1
cystitis 1
Table 3.6
Occurrence of clinical signs believed to be associated with FIV 
or FeLV infection
1 .FIV
no. 
FIV +
of cats 
FIV -
lymphadenopathy 25 131
diarrhoea 30 161
nervous signs 10 38
pyrexia* 115 359
gingiviti s/stomatitis* 67 163
anaemia 47 185
respiratory signs* 52 143
sick cats 317 1448
2.FeLV
no.
FeLV+
of cats 
FeLV-
lymphadenopathy 30 120
diarrhoea 22 156
pyrexia* 106 329
anaemia* 77 141
sick cats 276 1352
* denotes- significant difference by Chi-square analysis (p<.05)
for the prevalence of FIV infection in Japan [2], the USA [3] and 
France [38]. The levels of infection in the Netherlands, Germany 
and Switzerland, on the other hand, were significantly lower 
[38,42]. The reasons for this marked difference is not yet clear.
As well as health status having an effect on the prevalence of 
FIV, this survey provided evidence that age, breed and sex were 
also important factors. Other workers have suggested that the 
older, male cat is most likely to be infected with FIV [3,2]. The 
present findings would support these suggestions. Furthermore, 
this study indicated that breed has an effect and that an age-sex 
interaction exists. There does not appear to be any age-related 
susceptibility to infection with FIV as 6 month old cats are
susceptible to experimental inoculation (data not shown). The 
higher prevalence of FIV in older cats may reflect the long
latent period of this infection. An extended latent period would 
result in an accumulation of seropositive cats with time which 
would be consistent with observations on other lentiviruses, 
including HIV in man; and with the observation that cats
experimentally inoculated with FIV did not display clinical signs 
of immunodeficiency within 17 months of inoculation [3]. 
Alternatively, continued exposure to FIV may be required before a 
threshold is reached and an infection can develop.
The importance of breed which was observed is less likely to be 
associated with any genetic effect than with managemental 
factors. Pedigree cats, especially those kept for breeding 
purposes, are often housed in small groups and prevented from 
roaming outdoors. Many domestic cats, on the other hand, are
free-roaming with a greater opportunity to socialise with other 
cats than are pedigree cats. Cats which are free-roaming in this 
way are more likely to meet the feral cat population which is 
thought to have a high level of FIV infection (C Hopper, personal 
communication).
Differences in prevalence between sexes were noted. In male 
entires alone, the prevalence increased between each successive
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age group. In the other three sexes there was a decrease in 
prevalence in the oldest age group which may indicate that 
infection led to mortality in this age group. Alternatively, the 
cats in this age group could have ceased to be exposed to the 
factors necessary for infection, whereas entire male cats 
continued to be exposed to such factors.
When all male cats were compared to all female cats, it was seen 
that at each age the prevalence of FIV was greater in males than 
females. It has previously been suggested that since male cats 
are more inclined to fight than female cats, transmission of FIV 
may occur via biting [3,41]. The successful isolation of FIV from 
saliva is consistent with this theory [3]. Further controlled 
studies are, however, required to determine methods of 
transmission.
When the prevalence in entire and neutered cats was compared, 
there was a lower prevalence in neutered cats in the oldest age 
group. This could reflect either mortality in the infected 
neutered cats at this age, or a change in their behaviour or 
management, such that they were no longer exposed to conditions 
causing new infections.
For FeLV the prevalence was 18% in sick cats and 5% in healthy 
cats. A recent survey conducted in the USA reported prevalences 
of 13% in sick cats and 4% in healthy cats [41]. The present 
survey clearly demonstrated the different ages at which FIV and 
FeLV are most common. Whereas FeLV occurred predominantly in 
young cats, FIV was most prevalent in older cats. These findings 
are consistent with the concept that cats of all ages are equally 
susceptible to FIV and that FIV-associated diseases have a long 
latent period; and that, by contrast, young cats are much more 
susceptible to FeLV infection and the latent period to disease 
caused by that virus is relatively short. While previous 
experimental and epidemiological observations confirm the marked 
age-related susceptibility of cats for FeLV [75] and indicate a 
period of 3.5 years from infection to death in 85% of cats [76],
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there is limited information on these aspects of FIV infection.
The data from multi-cat households were examined for evidence of 
the relative transmissibility of FIV and FeLV. It should be noted 
that the multi-cat households in this study were not necessarily 
closed households. Cats in the smaller households were most 
likely free to roam outdoors, whereas the larger households, 
especially those containing pedigree cats, may have been closed.
Ishida et al [2] reported that 42% of 60 Japanese cats in contact 
with FIV were positive, whereas the level of infection was only 
21% in this survey of 229 cats in the UK. The households in the 
Japanese survey were not closed breeding catteries but animal 
shelters, or households where the cats were allowed to roam
outdoors. The management of the domestic cats in the households
examined in this survey was comparable and yet only 24% of in­
contacts had seroconverted.
One reason for the differences in the prevalence of FIV between 
households may be that there is variation in pathogenicity 
between different isolates of FIV. Some isolates may infect a 
higher proportion of cats in multi-cat households. In some of the 
large households in which FIV was detected in this survey, none 
of the cats , or only a single cat, had clinical signs. This 
contrasted with the households in the Japanese survey in which 
there were often chronic disease problems. Information relating 
to the length of time that the in-contacts had been exposed to 
FIV was not available.
It has been suggested that FIV is less efficiently transmitted 
than FeLV [77]. Our results, however, do not entirely support 
this view. The prevalence of FIV in in-contact cats in multi-cat
households was 21% which is similar to the 16% found for FeLV.
In FeLV-infected households, essentially all cats in contact with 
a viraemic cat become infected with the virus. From a previous 
study in the UK, approximately 24% were persistently infected 
and the remainder were recovered and were immune with serum
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neutralising antibodies [78]. In FIV households, however, it is 
not possible to determine whether seronegative cats have been 
infected with the virus but have failed to become persistently 
infected (since there is no known marker for 'recovered' animals) 
or if they have not been exposed at all.
This survey also provided some information on clinical signs 
associated with both FIV and FeLV. There were no groups of sick 
cats which were actively discriminated against in the selection 
of samples although bias may have arisen since the samples from 
sick cats had been submitted for virological examination and 
these cats were therefore most likely to be suffering from 
serious or chronic disorders. Although all of the sick cats were 
known to be showing clinical signs, specific signs were not 
always recorded on the submission form. Where clinical findings 
were noted, it was not possible to be confident that the omission 
of a sign correlated with its absence. For this reason, it was 
not possible to examine the combinations of clinical signs in 
FIV- positive or FeLV- positive cats.
Previous studies have shown an association between the presence 
of FIV antibodies and chronic stomatitis in the UK [44]. This
association was noted in the present study, as well as the
associations with pyrexia and respiratory signs. The 
classification of respiratory signs included both upper and lower 
respiratory tract disorders as in many cases these could not be 
differentiated using the information on the submission forms.
FeLV is a well established cause of anaemia [79] and this 
association was found to be significant, as well as the
association with pyrexia.
Later studies (reported in section 4.3.4) demonstrated that false 
positive results occurred in the ELISA test which was used in 
this survey. Therefore the false positives were classified 
according to health status, age, breed and sex in order to 
determine whether any goup was more likely to give a false
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positive result. This analysis showed that the false positives 
were equally distributed amongst all groups. Therefore the 
statistical analysis of this survey remained valid.
In conclusion, this survey indicates that the older, male, free- 
roaming cat is most likely to be infected with FIV. There is no 
age-related susceptibility to FIV, in contrast to FeLV which is 
most prevalent in young cats. FIV and FeLV act independently and 
are both significant pathogens where there is contact between 
cats.
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4. SEROLOGICAL RESPONSES TO FIV
4.1. INTRODUCTION
FIV infected cats have serum antibodies to the virus which are 
detected most conveniently by an ELISA. We have, however, noted 
that some reactions in this test are non-specific since no 
reactivity is demonstrable by immunoblotting. The purpose of this 
study was to identify the viral proteins of FIV and to examine 
the serological response to each protein following FIV infection 
in cats, using immunoblotting. The serological responses in cats 
naturally and experimentally infected with FIV were investigated. 
These immunoblot results were categorised according to reactivity 
of antibodies with individual viral proteins and were then
compared with the results of ELISAs. In this way a set of
criteria were established to identify FIV antibody-positive cats.
4.2. MATERIALS AND METHODS
4.2.1. Gel elecrophoresis
Infected cells were incubated at a concentration of 10^ cells per
o r
ml in methionine-free medium for 4 hours. A mixture of °°S L- 
methionine and L-cysteine (ICN Translabel) was then added to a 
final concentration of 100 uCi per ml in medium with 10% of the 
normal concentration of methionine and the culture was incubated 
overnight. The culture fluids were then filtered through a 0.22 
urn membrane and were centrifuged in a 20-50% sucrose gradient in
an SW41 rotor at 35,000 rpm for 60 minutes. The peak of
radiolabel at a density of 1.15 g.cm^ was collected, diluted to 5 
ml in tris-buffered saline and pelleted in an SW50.1 rotor at 35 
000 rpm for 60 minutes. The pellets were resuspended in SDS-PAGE 
sample buffer containing 500mM 2-mercaptoethanol and were 
electrophoresed in a 8-15% gradient SDS-PAGE gel. The gels were 
then treated with enhancer (Enlightning, NEN Research Products), 
dried and autoradiographed.
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4.2.2. Radioimmunoprecipitation
Infected cells were incubated overnight at a concentration of 10° 
cells per ml in glucose-free medium with 5 uCi per ml ^ C -  
glucosamine. The cells were then washed once with 0.14M NaCl, 
lOmM Tris pH 7.4 and resuspended in lysis buffer (100 mM Tris pH
7.4, 140 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% SDS, 0.5%
deoxycholate and 1% aprotinin). The cell lysate was mixed with 
cat anti-FIV antiserum and incubated for an hour before the 
addition of Protein A Sepharose CL-4B (Sigma). After incubating 
for an hour, the sample was washed several times, resuspended in 
SDS-PAGE sample buffer and electrophoresed in a 10% SDS-PAGE gel. 
The gel was then fixed, treated with enhancer, dried and
autoradiographed.
4.2.3. Immunoblotting
The immunoblot (Western blot) procedure was a modification of 
that previously described [80]. The antigen was prepared in one 
of two ways, either as concentrated virus or as a cell lysate.
To concentrate virus, culture fluids from infected cell cultures 
were clarified by centrifugation at 7 500 rpm for 20 minutes and 
filtered through a 0.45 urn membrane. The virus was then pelleted 
by ultracentrifugation at 36 000 rpm for 60 minutes and
resuspended in SDS-PAGE sample buffer.
To prepare a cell lysate, 2 x 10 ^ cells were washed out of
culture fluid and resuspended in 40 uls of lysis buffer. The
lysate was microfuged briefly to remove cell debris and SDS-PAGE 
sample buffer was added to the supernatant.
The antigens were resolved using the Biorad Minigel apparatus. 
Either 10% polyacrylamide gels or 10-20% gradient gels were used, 
the latter giving better resolution of the lower molecular weight 
proteins. The proteins were transferred to nitrocellulose and the 
remaining binding sites were blocked with 0.5% non-fat milk
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powder (NFMP) in Tris-buffered saline.
The nitrocellulose was cut into strips which were incubated with 
serum diluted 1:10 in 1.0 % NFMP and 0.5% Tween-20 in Tris 
buffered saline for two hours. The strips were washed several 
times in 0.5% Tween-20 in PBS and then incubated with 
biotinylated protein A for an hour. After further washing, the 
strips were incubated with streptavidin-alkaline phosphatase for 
an hour. The strips were washed once again before being developed 
with a substrate containing 5-bromo-4-chloro-3-indolyl phosphate 
and nitro blue tetrazolium as previously described [81].
4.2.4. Serum samples
Samples were obtained from specific pathogen free cats 
experimentally infected with the Petaluma (kindly provided by NC 
Pedersen), Glasgow-8 and Glasgow-14 strains of FIV. Field sera 
were obtained from cats by veterinarians in the UK.
All sera were tested using a commercially produced plate ELISA 
kit (PetChek Feline T-Lymphotropic Lentivirus Antibody Test Kit, 
Idexx Corp.) for the detection of anti-FIV antibodies [50]. The 
test was carried out according to the manufacturer's instructions 
and the absorbance of each well was read at 650nm. Results were 
expressed as a ratio (S/P) of the absorbance of each sample well 
to that of a control positive sample. Selected sera were also 
tested using the commercially produced CITE ELISA test (CITE 
Combo Kit, Idexx Corp., kindly provided by Pitman-Moore) for the 
detection of FIV antibodies and FeLV antigen.
4.3.> RESULTS
4.3.1. Viral proteins
The result of SDS-PAGE of ^ S  labelled virus is shown in figure 
4.1a. The Mr of the major bands were 24K (p24) and 17K (pi7) and 
of the minor bands, 120K and 10K. Additional faint bands were
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Figure 4.1
a .  A u t o r a d i o g r a p h  o f  ^ S - m e t h i o n i n e / c y s t e i n e  l a b e l l e d  F I V  
a n d  b .  R a d i o i m m u n o p r e c i p i t a i o n  o f  ^ C - g l u c o s a m i n e  l a b e l l e d  
i n f e c t e d  c e l l  l y s a t e .
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observed with Mr of 62K, 54K, 52K, 41K and 32K.
Radioimmunoprecipitation of ^C-glusosamine labelled infected 
cell lysate with a FIV-positive antiserum indicates that the 120K 
and 41K proteins were glyscosylated (Figure 4.1b).
4.3.2. Detection of antibodies to FIV proteins by immunoblotting.
Serum samples from cats experimentally infected with FIV were 
reacted in immunoblots with proteins prepared from concentrated 
virus. Antibodies were detected to p55, p24 and pi7 but there was 
no reactivity with a higher molecular weight putative envelope 
glycoprotein. It was considered that the glycoprotein may have 
been lost either into the culture fluid or during the 
purification procedure, or was not transferred to the 
nitrocellulose membrane. In an attempt to identify the 
glycoprotein on immunoblotting, the procedure was repeated using 
infected cell lysates as the antigen. The immunoblots prepared in 
this way revealed antibody to gpl20 indicating a loss of the 
glycoprotein during preparation of the concentrated virus.
As more information could be obtained using infected cell lysates 
rather than concentrated virus as antigen on immunoblots, cell 
lysates were used in all subsequent blots. The majority of blots 
with field sera were easily interpreted (Figure 4.2). However, a 
minority exhibited a number of apparantly non-specific bands. To 
ensure that the reactivity in sera was virus specific, a series 
of field sera were blotted against uninfected cell lysate as well 
as infected cell lysate (Figure 4.3). Some sera showed non­
specific binding to components in uninfected cell lysate, most 
notably at a molecular weight of approximately 60K, but this 
activity could be differentiated from the virus-specific bands 
seen at 55K. The bands at 120K, 24K and 17K were similarly shown 
to be virus-specific. Another band was seen with the sample in 
lane 3 at 10K which was assumed to be a third viral core protein.
51
a b c d e f
120 — ■
55-
24- I
17- P
Figure 4.2
I m m u n o b l o t s  o f  f i e l d  s e r a  a g a i n s t  F I V - G 1 a s g o w - 8 - i n f e c t e d  c e l l  
l y s a t e s .  A l l  s e r a  w e r e  i n  E L I S A  c a t e g o r y  A .  S e r a  i n  l a n e s  
a  a n d  d  w e r e  i n  i m m u n o b l o t  c a t e g o r y  6 ,  s e r a  i n  l a n e s  b ,  c  a n d  e  
w e r e  i n  i m m u n o b l o t  c a t e g o r y  1 a n d  t h e  s e r u m  i n  l a n e  f  w a s  i n  
i m m u n o b l o t  c a t e g o r y  3 .
a. b.
a b c d e MW
°200
092 
0 69
o46
a b c d e MW
T r j /  ;
o2 00
xSI 'r
o 30
1 20  
> ---
iJi1l?n
5 5 ^
24 ► j .
092
o69
o46
o30
i •
o21 10
o 14
o21
0 1 4
Figure 4.3
I m m u n o b l o t s  o f  s e r a  a g a i n s t  a .  u n i n f e c t e d  a n d  b .  F I V - i n f e c t e d  
c e l l  l y s a t e s .  L a n e  a :  s e r u m  i n  E L I S A  c a t e g o r y  B ,  i m m u n o b l o t  
c a t e g o r y  6 ;  l a n e s  b , c  a n d  d :  s e r a  i n  E L I S A  c a t e g o r y  A ,  i m m u n o b l o t  
c a t e g o r y  1; l a n e  e :  s e r u m  i n  E L I S A  c a t e g o r y  D ,  i m m u n o b l o t
c a t e g o r y  5 .  O p e n  a r r o w s  i n d i c a t e  n o n - s p e c i f i c  b a n d s  s e e n  a g a i n s t  
b o t h  i n f e c t e d  a n d  u n i n f e c t e d  c e l l  l y s a t e s .
4.3.3. Development of immune responses to viral proteins in 
experimentally infected cats
The antibody response to individual viral proteins was followed 
in cats which were experimentally inoculated with FIV. Serum
samples were taken prior to infection and then at three week
intervals from cats infected with the Glasgow-8 strain of FIV.
These samples were used in immunoblots against FIV-infected cell
lysates. It was seen that antibodies developed first against p24
and subsequently against pl7 and p55. The cats which
seroconverted by 6 weeks post infection (pi) had been infected 
with a greater dose of virus than those which seroconverted at 9 
weeks pi. Antibody to the high molecular weight glycoprotein 
appeared at the same time as pi7 and p55 (Figure 4.4). All of 
these anti-FIV antibodies were still detectable 45 weeks post
infection. Sequential samples taken from cats experimentally 
infected with both the Petaluma and Glasgow-14 strains of FIV 
gave similar results to the cats infected with the homologous 
virus (Figure 4.5).
4.3.4. Comparison of plate ELISA and immunoblot results
The results of the plate ELISA test were read at 650nm and the 
S/P ratio was calculated as previously described [50]. According 
to the manufacturer, samples with ratios equal to or greater than 
0.5 are positive for antibody to FIV. For the purposes of this 
study, S/P ratios were further classified into 4 groups: group A 
with ratios greater than 1.5, group B with ratios between 0.5 and
1.5, group C with ratios between 0.2 and 0.5, and group D with 
ratios less than 0.2.
The results of the immunoblots were classified into groups 
according to the confidence with which they could be designated 
positive or negative. Group 1 contained those samples which 
showed bands against gpl20 and at least one core protein. Group 2 
contained samples with a band against gpl20 but no core proteins. 
Group 3 samples reacted against three or four of the core
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Figure 4.4
S e q u e n t i a l  i m m u n o b l o t s  o f  s e r u m  s a m p l e s  f r o m  a c a t  e x p e r i m e n t a l l y  
i n f e c t e d  w i t h  F I V - G 1 a s g o w - 8 . L a n e  a :  s a m p l e  t a k e n  p r i o r  t o  
i n f e c t i o n ;  l a n e s  b  t o  f :  s a m p l e s  t a k e n  a t  t h r e e  w e e k l y  i n t e r v a l s  
p o s t  i n f e c t i o n ;  l a n e  g :  s a m p l e  t a k e n  6  m o n t h s  p o s t  i n f e c t i o n .
Figure 4.5
I m m u n o b l o t s  o f  s e r u m  s a m p l e s  t a k e n  f r o m  c a t s  1 5  w e e k s  a f t e r  
e x p e r i m e n t a l  i n f e c t i o n  w i t h  a .  F I V - P e t a l u m a ,  b .  F I V - G 1  a s g o w - 8  a n d  
c .  F I V - G 1 a s g o w - 1 4  a g a i n s t  F I V - G 1 a s g o w - 8 - i n f e c t e d  c e l l  l y s a t e s .
proteins (p55, p24, pl7 and plO). Samples in groups 1 to 3 were 
regarded as positive. Samples in groups 4 and 5 reacted with two
and one core protein respectively and samples in group 6 showed
no virus-specific bands. Samples in groups 4 to 6 were regarded 
as negative.
4.3.5. Serological responses in naturally infected cats
A series of 68 samples from cats which had been diagnosed FIV 
antibody negative and 215 samples from cats diagnosed FIV 
antibody positive by ELISA were tested by immunoblotting against 
infected cell lysate (Table 4.1). All samples which were ELISA- 
negative were negative on immunoblotting. Of the samples which 
were ELISA-positive according to the manufacturer, 57/215 (26.5%) 
were in immunoblot categories 4 to 6 and were therefore regarded 
as negative. Of the samples in ELISA group A (with S/P ratios of 
>1.5), only 10/125 (8%) were negative by immunoblotting.
4.3.6. Comparison of three ELISA systems
A series of 30 selected samples were tested using immunoblotting, 
the old plate ELISA used in this study, the CITE test for FIV
antibodies as well as by the new format plate ELISA. Of these 30
samples, 7 were positive and 3 were negative by all four tests.
Of the remaining 20 samples, 15 were positive by the old plate 
test but were negative by immunoblotting, the CITE test and the 
new plate test. These samples therefore appeared to be false
positives by the old plate ELISA test. One sample was positive
using the old plate test and the CITE test but negative using 
immunoblotting and the new plate test. These samples were 
presumably false positives by the old plate and CITE tests.
Two samples were negative by the new plate test but positive by 
immunoblotting, the CITE test and the old plate test. These 
samples therefore appeared to be false negatives by the new plate
test. One sample was negative by CITE but positive by the other
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Table 4.1
Comparison of plate ELISA S/P ratio and immunoblot results
immunoblot category 
1 2 3 4 5 6
A 99 2 14 5 3 2
ELISA B 36 6 1 4 10 33
category C 0 0 0 1 9 25
D 0 0 0 0 5 28
three tests and was presumably a false negative by the CITE test.
One sample was positive by immunoblotting (having antibodies 
against both envelope and core proteins) but was negative using 
the other three tests.
Therefore, it appeared that false positive results were most 
common with the old plate test, but were occasionally seen with 
the other ELISA tests. Of the three ELISA tests, the CITE test 
correlated most closely with the results obtained by 
immunoblotting, followed by the new plate test. However, it was 
suspected that occasional false negative results arose with these 
two test kits.
4.4. DISCUSSION
This study confirmed that the protein content of FIV is similar 
to that of HIV [82]. Thus, the presumed major core proteins are 
p24, pl7 and plO with a possible precursor, p55. Two glycosylated 
polypeptides, gpl20 and gp41, are probably the envelope 
glycoproteins of the virus. The additional polypeptides observed 
in radiolabelled virus may represent products of the £ol_ gene.
Cats infected naturally or experimentally with FIV make 
antibodies to several of these proteins. This study demonstrated 
the order of appearance of antibodies against both core and 
envelope proteins of FIV whereas others have also reported the 
appearance solely of anti-core antibodies in sequential samples 
from experimentally infected cats using immunoblot analysis 
[3,50].
From these results it is clear that the reason for the lack of 
gpl20 in immunoblots made with concentrated virus is that this 
protein is lost from the virus during production or purification. 
Similar findings have been made with HIV. The use of FIV infected 
cell lysates as antigen for blots is a convenient method of 
overcoming this problem and permitting the detection of anti-
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gpl20 antibodies.
It would appear that the timing of the appearance of antibodies 
following infection is dependent on the dose of virus used. Those 
cats which received the lowest dose of virus were first seen to 
seroconvert at 9 weeks pi whereas those which were infected with 
the highest dose began to seroconvert by 6 weeks pi. The long 
time course of continued antibody response demonstrated in this 
study has also been seen by others [50] and is consistent with 
the persistent nature of the infection. In this study, the cats 
which had been experimentally infected with FIV showed no overt 
signs of clinical disease, the longest period of infection being 
45 weeks. This finding would suggest that FIV infection, as HIV 
infection, has a long incubation period. Various organs of these 
cats did however, display histological lesions of an early AIDS 
type (WFH Jarrett, personal communication).
The similar patterns of seroconversion seen in sequential samples 
from cats infected with different isolates of FIV suggests that 
there are conserved epitopes between these three isolates. Field 
sera, however, did not consistently react against both envelope 
and core proteins. It is conceivable that had the cats which had 
been experimentally infected with FIV been monitored until the 
time of death, there would have been a change in the serological 
reaction on immunoblots. In early and asymptomatic HIV infection 
in man, antibodies to p24 predominate, whereas with progression 
to AIDS, the antibody titre to p24 declines or disappears [83]. 
We are currently investigating whether field samples from 
seropositive cats show variable responses on immunoblots 
according to the stage of infection as well as whether there are 
possible strain differences.
The criteria for classifying samples as seropositive by 
immunoblotting were selected on the basis of the pattern shown by 
sera from experimentally infected cats as well as by analogy with 
HIV diagnosis. The minimum requirement of antibody to gpl20 or to 
at least three core proteins may need to be redefined if further
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studies indicate that virus can be isolated from cats which do 
not meet these criteria. Examining immunoblots for reactivity 
against gp41 may be of value in interpreting results but so far 
it has not been possible to consistently reproduce lysates 
containing gp41.
A previous study tested by immunoblotting 141 samples from field 
cats which were positive by plate ELISA [50]. The criteria for a 
positive result by immunoblotting in that report was staining of 
two or more FIV polypeptides. Four of the 141 samples were 
reactive to only a single FIV protein (p26 or pl5) and the 
remainder showed bands to p26 and pl5, with variable reactivity 
to proteins of 10, 32, 40, 47 and 65 kilodaltons. The four 
samples which were negative by immunoblotting were, however, 
positive by the RIPA-SDS-PAGE assay in which reaction to gpl20
was required for confirmation. That report, therefore, did not 
reveal any false positive plate ELISA test results. In contrast, 
the present study demonstrated the existence of false positive
results in this ELISA test. Even if the same criteria were
applied as in the earlier paper (namely that the presence of 
reactivity against only two core proteins on an immunoblot could 
be regarded as positive), 48/215 (22%) of plate positive samples 
in the present study were negative on immunoblotting. Neither 
study revealed any discordance between the tests if the samples 
were negative in the plate ELISA.
The plate ELISA test wells are coated with FIV antigen prepared 
from a feline cell line [50]. In the CITE ELISA test, the antigen 
is membrane bound and a prefilter is used to remove insoluble 
material in the plasma. The comparison between the three ELISA
tests suggested that the CITE test had a higher specificity
compared to the old plate test. The immunoblots against
uninfected cell lysates demonstrated that some cat sera contain
antibodies which react with lysates from normal feline cells.
Hence, it is possible that feline cell antigens on the ELISA 
wells bind antibodies non-specifically, resulting in false 
positives.
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The new plate test was designed to eliminate false positive 
results by incubating the sample with antigen linked to horse- 
radish-peroxidase (HRPO) (Tom O'Connor, personal communication). 
Anti-FIV antibodies in the sample cross-link the plate-bound 
antigen and the HRPO-1inked antigen, thereby giving a positive 
result. The results of this study confirm that the new test 
format has indeed eliminated the false positive results which 
were observed with the old test but suggest that there may be 
some false negative results with the new test. False negatives 
may occur if the assay cut-off is too stringent.
An ELISA test using recombinant FIV p24 has been developed to 
measure anti-p24 antibodies [84]. As the ELISA wells are coated 
with a pure preparation of p24 expressed in Escherichia coli (in 
contrast to the commercial ELISAs which use virus purified from 
feline cells) this test is very specific. When the anti-p24 
antibody test was evaluated by comparison with immunoblotting, 
the results were in agreement for the majority of samples. There 
was, however, an intermediate range of absorbances for which the 
results were indeterminate. Therefore this test was valuable for 
screening large numbers of samples, combined with the use of 
immunoblotting for indeterminate samples.
The phenomenon of false positive results was observed in the 
early testing of human blood donor sera for anti-HIV antibodies 
[85]. From a sample of 3961 donors, 9 were positive on an initial
ELISA test and of these, 4 remained postive when the test was
repeated. Only 2 samples were confirmed as being positive by 
immunoblotting, having antibodies against p24, p41 and p64.
Seroconversion did not occur in 2 recipients of blood that was
consistently ELISA positive but immunoblot-negative. In contrast, 
the 2 recipients of immunoblot-positive blood seroconverted 6 and 
8 weeks after transfusion.
It was important in this study to establish a set of criteria for 
a positive immunoblot result as not all sera contained antibodies
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against both envelope and core constituents. Those sera which 
reacted against 3 or 4 core proteins but not against gpl20 may 
have been from cats infected with an isolate of FIV with a gpl20 
antigenically distinct from that of FIV-G1asgow-8. This reaction 
was designated positive in this study. Sera reacting against only 
two or fewer core proteins, on the other hand, were classified as 
negative. Similarly, in HIV testing, it has been found that 
isolated anti-p24 and anti-p55 (without any anti-gpl20/160) 
probably represents a false positive reaction [86,87,88,89]. A 
patient with a false positive immunoblot with both anti-p24 and 
anti-p41 has also been reported [90]. Another type of false 
positive has been reported which displays a strong reaction to 
pl3 and a weak reaction with p55 [88].
Reactivity to only the p24 protein of HIV in immunoblot analysis 
was often observed in early HIV infection [83,85]. It has been 
shown, however, that when blotted against antigen enriched for 
gpl20/160, such sera also show reactivity to gpI20/160 [89].
The results of this study demonstrated further similarities 
between FIV and HIV, as well as providing useful information for 
the diagnosis of FIV infection in the cat.
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5. IN VITRO CELL TROPISM OF FIV
5.1 INTRODUCTION
This chapter describes the initial isolation of FIV and the 
subsequent efforts to produce large amounts of virus for the 
studies described elsewhere in this thesis. Various feline cell 
lines were compared for their ability to support the growth of 
FIV. Q201 cells, which were shown to be highly susceptible to FIV 
infection, were examined by flow cytometric analysis at intervals 
after infection and changes in the expression of cell surface 
markers were detected. Subsequently a monoclonal antibody (vpgl5) 
was identified which blocked FIV-8 infection of both Q201 cells 
and CRFK cells. Thus there was strong evidence that the FIV-8 
receptor was recognised by vpgl5.
Initially, to isolate FIV from infected cats, selected sera were 
screened for anti-FIV antibodies by immunofluorescence using T- 
cells infected with the Petaluma strain of FIV (FIV-P). Sera were 
selected on two criteria. Firstly the cats had to show signs of 
immunodeficiency and secondly their sera had to be FeLV-negative. 
One isolate, namely FIV-Glasgow-8, was selected and was 
subsequently used for all work described in this thesis.
5.2. MATERIALS AND METHODS
5.2.1. Isolation of FIV-Glasgow-8
5.2.1.1. Infection of T-cells with plasma
T-cell cultures of 2mls were set up at a cell concentration of 2 
x 10^ cells per ml in normal T-cell medium. Samples of blood 
plasma were diluted in normal T-cell medium (200uls plasma per 
ml), filtered through a 0.45um filter and incubated with the 
cells overnight. The following day the cells were washed and the 
concentration was adjusted to 5 x 10^ cells per ml. The cultures 
were examined daily for the appearance of cytopathic effect and
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when this was evident the cells were pelleted and fixed for 
electron microscopic examination.
FIV was isolated from the plasma of 3 cats, thus indicating that 
cell-free infectious virus was present in these cats. These 
isolates were designated FIV-Glasgow-8 (FIV-8), FIV-Glasgow-14 
(FIV-14) and FIV-Glasgow-15 (FIV-15). The following information 
was available for each cat:
Cat 8: 6 year old entire male domestic shorthaired cat 
pyrexia, respiratory signs, lethargy, 
anorexia, weight loss
Cat 14: aged entire male domestic longhaired cat 
pyrexia, weight loss, lymphadenopathy
Cat 15: 13 year old neutered male cat 
weight loss, lymphadenopathy
The cytopathic effect appeared in the cultures between 7 and 14 
days in culture. Ballooning cells appeared first, followed by 
degeneration and syncytium formation (Figure 5.1). When examined 
using the electron microscope, particles of approximately 120nm 
diameter and displaying typical lentivirus morphology were found 
(Figure 5.2).
5.2.1.2. Isolation of FIV-8 from cultured T-cells
Two months after the initial sampling, a 5ml heparinised blood 
sample was obtained from cat 8 above. The sample was diluted to 
20mls in RPMI-1640, layered over 5mls Ficoll-Paque solution and 
centrifuged at 2000rpm for 10 minutes. The white cells at the 
interface were carefully pipetted into a clean tube, diluted to 
25mls in RPMI-1640 and centrifuged at lOOOrpm for 5 minutes. The 
cell pellet was resuspended in 5mls normal T-cell medium to which 
Con A had been added (7.5ug per ml). After 2 days in culture, the 
unattached cells were washed out of the medium containing Con A
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Figure 5.1
F e l i n e  p e r i p h e r a l  b l o o d  T - c e l l s  a .  u n i n f e c t e d  a n d  b .  i n f e c t e d  
w i t h  F I V ,  s h o w i n g  a  c y t o p a t h i c  e f f e c t  w i t h  s y n c y t i u m  f o r m a t i o n .
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Figure 5.2
E l e c t r o n  m i c r o g r a p h  o f  F I V  p a r t i c l e s  i n  a c u l t u r e  o f  f e l i n e  
p e r i p h e r a l  b l o o d  T - c e l l s  ( c o u r t e s y  o f  D r  H  L a i r d ) .
and were transferred to a fresh flask containing 5mls normal T- 
cell medium. The culture medium was changed twice weekly and the 
cell concentration adjusted to 5 x 10^ cells per ml. Once a week 
susceptible cells from a normal cat were added to the culture and 
whenever necessary the dead cells were removed from the culture 
by density gradient centrifugation using Ficoll-Hypaque solution.
After 5 days in culture there was evidence of ballooning 
degeneration of cells and syncytium formation. The addition of 
uninfected T-cells resulted in a massive cytopathic effect over 
the following 2 or 3 days. If uninfected cells were not added to 
the culture, virus production decreased as the cells which were 
susceptible to infection died.
5.2.2. Titration of FIV-8 in normal T-cells and P51 cells
Two types of cell were used initially to grow FIV-8, normal cat 
T-cells and P51 cells. Both cells showed ballooning degeneration 
and syncytium formation with FIV-8 infection but this appeared to 
be more marked in P51 cells. To compare the relative 
susceptibilities of the two cell types, FIV-8 stock A was 
titrated in each.
Ten 5ml cultures of each cell type were set up in 25cm^ flasks 
containing 5 x 10^ cells. Each culture was incubated overnight 
with five-fold dilutions of FIV-8 stock A, starting at 1 in 5. 
The medium was changed every three days. Cultures were assayed 
for virus production using the immunoblotting method described in 
section 4.2.3. Briefly, cell lysates were made (1 x 10^ cells per 
lOuls lysis buffer) at 6 and 12 days post infection. The proteins 
were separated by SDS-PAGE and blotted onto nitrocellulose. A 
polyclonal cat anti-FIV serum was used to stain the 
nitrocellulose membrane and infected cultures were identified by 
the presence of viral proteins.
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5.2.3. Cell tropism studies
5.2.3.1. Preparation of virus and virus-infected cells
Cultures of Q201 cells were infected with tissue culture 
supernatants containing FIV-P and FIV-8. After 24 hours the cells 
were washed out of the infected supernatant and the cells were 
resuspended in normal T-cell medium. The cultures were maintained 
for a week and susceptible cells were added. The culture 
supernatants were tested for FIV antigen by ELISA and when high 
titres were obtained the cells and supernatants were used for 
infections. Both cultures gave comparable ELISA titres.
The cells were pelleted, resuspended in 3mls normal T-cell medium 
and irradiated in a cobalt-60 source with a dose of 3000 rads. 
The cells were then washed twice in medium before co-cultivation. 
The infected supernatant was filtered using a 0.45um filter to 
remove cell debris before being used in infections.
5.2.3.2. Co-cultivations with infected cells
The suspension cells used in this experiment were Q201, 3201,
FL74, F422, F422-MD, T3 and McCoy cells. The monolayer cells used 
were 3 types of CRFK cells (ID10, H06TI and MCGMI) and AH927 
cells. Co-cultivations were set up with either 10® FIV-infected 
Q201 cells and 4 x 10® suspension cells or 10® FIV-infected Q201 
cells and 2 x 10® freshly trypsinised monolayer cells.
5.2.3.3. Infection of cells with supernatants
Cultures of 5 x 10® suspension cells and 3 x 10® monolayer cells 
were infected with 1ml FIV-infected supernatant (the supernatant 
equivalent of 10® cells) in 4mls medium. Control cultures were 
set up without infected supernatnant.
C-f
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5.2.3.4. Maintenance of cultures
The cultures were incubated overnight either with infected cells 
or with infected supernatant. The following day the suspension 
cells were centrifuged and were resuspended in 5 mis medium. The 
monolayers of cells were washed and new medium was added. The 
cells were subcultured every 5 days, the cell concentration of 
the suspension cells being adjusted to 10^  per ml and the 
monolayer cells being subcultured at a ratio of 1 in 4. 
Uninfected cells were treated in an identical fashion. The 
cultures were tested at weekly intervals for 4 weeks for the 
appearance of FIV antigen by ELISA.
5.2.4. Use of monoclonal antibody to block FIV infection of Q201 
cells
Four cultures, each containing 5 x 10^ Q201 cells were incubated 
with solutions of different monoclonal antibodies in 1ml normal 
T-cell medium at 37°C for 30 minutes. The monoclonal antibodies 
used were vpg30 (anti-fCD4), vpgl5 and a monoclonal antibody 
against cat IgA. All antibodies were provided by Tom Dunsford. 
The antibodies were added to a final dilution of ascites of 
1/200. The fourth culture was incubated in medium without the 
addition of antibody as a control. Each culture was centrifuged 
at lOOOrpm for 5 minutes, the supernatant was discarded and the 
cells were resuspended in FIV-8-infected supernatant containing 
antibody as in the first incubation. The cells were incubated 
with the virus at 37°C for 30 minutes before being washed twice 
and resuspended in normal T-cell medium containing a maintenance 
solution of antibody (1/500 dilution of ascites). The cells were 
subcultured 3 days post-infection and were maintained in culture 
for a week. Samples of supernatant were taken daily for 
measurement of p24 production by ELISA.
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5.2.5. Use of monoclonal antibody to block FIV infection of CRFK 
cells
CRFK (ID10) cells were seeded onto 24-well plates overnight at a 
concentration of 2 x 10^ cells per well. The following day the 
medium was removed and the cells were incubated at 37°C for 30 
minutes with two-fold dilutions of vpg30 and vpgl5, starting at 
1/100. The cells were then incubated with FIV-8-infected 
supernatant (derived from CRFK cells) containing antibody 
solution at 37°C for 30 minutes. The cells were then washed twice 
and medium containing maintenance antibody (1/5 dilution of 
antibody solution used to treat cells prior to infection) was 
added. The cells were maintained in culture for 4 days. Control 
wells were not incubated with antibody but were incubated with 
virus or were incubated with neither antibody nor virus.
The infection of CRFK cells after antibody treatment was assayed 
by immunohistochemical staining to detect p24 antigen. The cells 
were fixed in methanol for 20 minutes, washed in phosphate- 
buffered saline (PBS) and were incubated in 4% normal goat serum 
in PBS for an hour. After 3 PBS washes, an anti-p24 monoclonal 
antibody (kindly provided by Niels Pedersen) was added (1/3000 
dilution in PBS) for an hour. After 3 PBS washes, biotinylated 
anti-mouse immunoglobulin (Vector Laboratories, UK) was added at 
a dilution of 1/2000 and was incubated for 15 minutes. The cells 
were washed three times in PBS and were then incubated with 
streptavidin-peroxidase (Sigma, UK) which was used at 1/1000 in 
PBS for a further 15 minutes. After 3 PBS washes the substrate 
solution (0.04% ami no-ethyl carbazole in 0.05M acetate buffer pH 
5.0 containing 0.05% hydrogen peroxide) was added for 10 minutes 
and the reaction was stopped by rinsing the wells in distilled 
water. The wells were examined under a light microscope for red- 
staining foci of infection expressing p24 antigen and these foci 
were counted.
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5.3. RESULTS
5.3.1. Titration in normal cat T-cells and P51
Normal cat T-cells were consistently infected with the first four 
dilutions of FIV-8 stock A, ie. to 1/625. P51 cells were infected 
with a 1/3125 dilution on one occasion and with 1/15625 on 
another. Hence P51 cells were more susceptible to FIV-8 than 
normal T-cells.
5.3.2. Cell tropism studies
The susceptibility of cell lines to productive infection with
FIV-8 and FIV-P are shown in Table 5.1. Each cell line was also
examined for cell markers by flow cytometric analysis. The cells 
were stained with a panel of monclonal antibodies and the 
phenotypes are shown in Table 5.1 (Brian Willett, personal 
communication).
The cells which were susceptible to FIV-8 (Q201, F422 and T3) 
gave positive ELISA results from week 1, both with co-cultivation 
and with supernatant infection. The suspension cells which were
susceptible to FIV-P (Q201, F422, F422-MD, T3 and McCoy) also
gave positive results from week 1. The CRFK cells, on the other 
hand, became positive at various times. The ID10 cells became 
positive with supernatant at week 1 and with co-cultivation at 
week 3. The H06TI cells became positive with supernatant at at 
week 3 and with co-cultivation at week 2. The MCGMI cells became 
positive with supernatant at week 2 and with co-cultivation at 
week 3.
5.3.3. Expression of cell markers in FIV-infected Q201 cells
Q201 cells infected with FIV-8-infected supernatant were examined 
daily for the expression of fCD4 and the molecule recognised by 
vpgl5. The FIV-8-infected Q201 cells and a control culture of 
uninfected Q201 cells were analysed using flow cytometry. The
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Table 5.1
Cell phenotypes and susceptibility to infection with two isolates 
of FIV
cell cell markers susceptible
1 ine fpanT1 fCD42 fCD83 class I4 class II5 vpg!56 FIV-8 FIV-P
Q201 + +a - + + +a + +
3201 + + + + + - - -
FL74 + - - + + - -
F422 + - - + + + + +
F422-MD + - - - - +
T3 + - - - + + +
McCoy - - - + - + - +
ID10 - - - + - + _ +
H06TI - - - + - + - +
MCGMI - - - + - + - +
AH927 - - - + - + - -
* monoclonal provided by Christopher Ackley [91]
^ monoclonals provided by Christopher Ackley [92] and Tom Dunsford 
^ monoclonal provided by Max Cooper [93]
^ monoclonal provided by John Hopkins [94]
® monoclonals provided by Niels Pedersen and Tom Dunsford 
® monoclonal provided by Tom Dunsford
a decreased expression with infection with FIV-8
differences between the percentages of uninfected and infected 
cells expressing each marker are shown in figure 5.3 (data kindly 
provided by Brian Willett). It was demonstrated that there was a 
decreased expression of both fCD4 and the molecule recognised by 
vpgl5 in FIV-infected cells in vitro. In cells which had been 
infected with FIV-8 for 28 days, however, the expression of fCD4 
appeared to return to normal levels whereas there was still a 
decreased expression of the molecule recognised by vpgl5.
5.3.4. Blocking of FIV infection
While pretreatment of Q201 cells with monoclonal antibodies 
against fCD4 and cat immunoglobulin A did not alter the course of 
infection with FIV-8, pretreatment with vpgl5 blocked infection 
(Figure 5.4). Similarly in CRFK cells, vpgl5 increasingly blocked 
FIV-8 infection as the antibody concentration increased (Figure 
5.5), thus demonstrating that the effect was vpgl5-dependent.
5.4. DISCUSSION
The first isolation of a local FIV isolate was made from plasma, 
demonstrating that virus may be free in plasma as well as cell- 
associated. Subsequently, it was found to be easier to isolate 
FIV from peripheral blood T-cells rather than serum or plasma 
which suggested that FIV was highly T-lymphotropic.
The clinical signs demonstrated by the cats from which these 
first isolates were made displayed non-specific clinical signs of 
an immunodeficiency-type disorder, similar to those reported by 
Pedersen et al [1] and Harbour et al [51]. From several isolates 
of FIV, FIV-8 was chosen for the studies in this thesis. This 
isolate was from a cat which was suffering from a very acute 
episode of disease and in tissue culture produced a marked 
cytopathic effect. It was necessary to grow large quantities of 
virus to examine the viral proteins, to make diagnostic reagents, 
for in vivo pathogenesis experiments and ultimately for 
constructing vaccines. Therefore, atempts were made to grow FIV-8
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Figure 5.3
The differences in the percentages of uninfected and FIV-8- 
infected Q201 cells expressing fCD4 and the molecule recognised 
by vpg!5 at daily intervals after infection.
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Figure 5.4
The levels of p24 in supernatants of Q201 cells infected with 
FIV-8 after incubation with anti-cat IgA, anti fCD4, vpgl5 and 
antibody-free medium. The culture supernatants were tested daily 
by ELISA.
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Figure 5.5
The number of foci staining for p24 in cultures of CRFK cells 
infected with FIV-8 after incubation with two-fold dilutions of 
vpgl5 and anti-fCD4 antibody. The cells were stained 4 days post­
infection.
in a variety of cell lines.
Initially, virus growth was assayed by the examination of 
infected cultures for the appearance of cytopathic effect, 
followed by electron microscopy and the identification of 
lentivirus particles. Subsequently, FIV antigen production was 
detected by immunoblotting cell lysates using the technique 
described in section 4.2.3. Later experiments used the recently 
developed commercial ELISA to measure p24 production.
As growth of FIV in peripheral blood T-cells and P51 cells
required large amounts of recombinant human IL-2 as well as a 
supply of fresh, uninfected cells, attempts were made to grow FIV 
in other cell lines. The titration of FIV-8 in cells 
demonstrated that P51 cells were more susceptible to infection 
compared to normal cat T-cells. When examined by FACS analysis, 
it is seen that whereas normal cat T-cells are both fCD4+ and 
fCD8+, P51 cells are exclusively fCD4+. This suggested that fCD4 
may have an important role in FIV infection.
The CD4 molecule has been shown to be the cellular receptor for
HIV. It is a glycoprotein of 60 kilodaltons (kD) which is
expressed on the cell membrane of mature T-lymphocytes and, to a 
lesser extent, on cells of the monocyte/macrophage lineage.
Traditionally, CD4+ T-cells have been ascribed the function of 
helper/inducer cells, activating B-cells and cytotoxic T-cells. 
CD4+ T-cells interact with antigen-presenting cells which carry 
the major histocompatibility complex (MHC) class II antigen.
The relationship between CD4+ helper/inducer T-cells and 
infection with HIV was first suggested when the peripheral blood 
of AIDS patients was found to be depleted of CD4+ T-cells [22]. 
In vitro studies with HIV demonstrated a tropism for CD4+ cells
[23] and infection of cells by HIV was inhibited by monoclonal
antibodies directed against CD4 [23,24]. Furthermore, gpl20, the 
envelope glycoprotein of HIV, binds to CD4 with high affinity
[95], cells which are normally resistant to HIV infection become
67
susceptible when transfected with a CD4 expression vector [96] 
and recombinant soluble CD4 blocks HIV infection [26].
Hence it was important to investigate the role of fCD4 in FIV 
infection as this could provide a useful model for HIV infection. 
Therefore, various feline cell lines with different phenotypes 
were used to determine whether or not there was any correlation 
between the presence of fCD4 on the cell surface and 
susceptibility to infection with FIV. The susceptibility of cells 
to both FIV-P and FIV-8 were compared.
The co-cultivations in this experiment used irradiated FIV- 
infected cells to eliminate false positive results in the ELISA 
for FIV antigen arising as a result of release of virus from 
replicating FIV-infected cells. Also, preliminary experiments had 
shown that co-cultivation of T-cells with monolayer cells 
resulted in damage to the monolayer cells and therefore it was 
hoped that the use of irradiated cells would permit cell contact 
whilst still preserving the monolayer cells.
The results show that the two isolates used in this experiment 
had different cell tropisms. The differences could not be 
attributed to different virus concentrations as the two virus 
stocks gave comparable titres on ELISA.
The FIV-P stock had a wider cell range compared to FIV-8. It is 
possible that FIV-P had become more adapted to growth in tissue 
culture compared to FIV-8. Both viruses had been propagated in 
peripheral blood T-cells or thymocytes while in our laboratory 
but the early passage history of FIV-P was probably in CRFK 
cells.
In an earlier experiment it was possible to infect 3201 cells 
with FIV-8 (although the initially high level of virus production 
declined to negligible levels after several weeks). FIV-8- 
infected Q201 cells were co-cultivated with 3201 cells in the 
presence of recombinant human IL-2 for one week. When the IL-2
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was removed from the medium FIV continued to be produced, as 
shown by immunoblotting. Virus produced by these 3201 cells 
appeared to have an envelope glycoprotein of only 110K (compared 
to 120K in Q201 cells) but this result was not reproducible. The 
FIV-8-infected 3201 cells were then co-cultivated with CRFK cells 
which also became infected. Neither 3201 cells nor CRFK cells 
could be infected with supernatants from Q201 cells although they 
could be infected with supernatants from FIV-infected 3201 or 
CRFK cells respectively.
From these early experiments and the more controlled experiment 
using irradiated cells for the co-cultivations, it would appear 
that FIV can become adapted for growth in many cell lines. In the 
co-cultivations where IL-2 was included there was an increased 
interval for cell contact as the infected cells remained viable 
while IL-2 was present. It could therefore be hypothesised that 
in the co-cultivations with irradiated infected cells there was 
inadequate time for infection to occur. Alternatively, each 
isolate of FIV-8 may contain several different strains of virus 
with different cell tropisms and when the virus appears to become 
adapted to a different cell line the predominant strain changes. 
The early finding that FIV-8-infected 3201 cells infected CRFK 
cells would be consistent with this theory.
Phillips et al [97] have shown that a molecular clone of FIV-P 
replicates well in CRFK cells but less efficiently in T-cells. 
This experiment, however, shows that our stock of FIV-P is highly 
infectious for T-cells and therefore supports the theory that 
each isolate consists of a mixture of virus strains.
Although it was possible to demonstrate a decrease in fCD4 
as well as vpgl5 expression in FIV-8-infected Q201 cells, it was 
not possible to correlate susceptibility to infection with the 
presence of fCD4 on the cell surface. 3201 cells which expressed 
high levels of fCD4 could only be infected by long-term co­
cultivation in the presence of IL-2. Furthermore, some fCD4- cell 
lines, such as CRFK, could be infected with FIV.
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Nevertheless, some CD4- cell lines (such as brain and muscle- 
derived cell lines) can be infected with HIV, although with low 
efficiency since co-cultivation with CD4+ infected cells is 
necessary for infection [98]. It has also been suggested that 
CD4 independent infection can occur when anti-HIV antibodies 
allow uptake of virus by Fc receptor-bearing cells [99]. 
Therefore these results do not rule out the possibility that fCD4 
has a role in FIV infection.
However, the molecule recognised by vpgl5 is present on all cell 
lines which have been infected with FIV so far. Therefore, this 
molecule was a more likely candidate for the FIV receptor than 
fCD4. The demonstration in both Q201 and CRFK cells that vpgl5 
could block infection with FIV-8 provided strong evidence that 
vpgl5 recognised the FIV receptor. As the antibody was produced 
by inoculation with pelleted tissue culture supernatant derived 
from FIV-8-infected thymocytes, it is likely that the inoculum 
contained the receptor molecule attached to the virus.
Further evidence that the molecule recognised by vpgl5 is the FIV 
receptor was provided by the demonstration of a decreased 
expression of the molecule in FIV-infected cells in vitro. As the 
expression of fCD4 was also shown to decrease, it remains 
possible that fCD4 also has a role in FIV infection. Although 
vpg30 did not block FIV-8 infection, it is possible that 
antibodies against different epitopes would inhibit infection. 
Indeed, the cells which are most susceptible to FIV infection
remain Q201 cells which are exclusively fCD4+, suggesting an
important role for this molecule.
Further experiments have suggested that the molecule recognised 
by vpgl5 is the low affinity Fc receptor, equivalent to human 
CD16 (Brian Willett, personal communication). This molecule is 
present on neutrophils, macrophages and activated T-cells. As
Q201 cells are activated T-cells, it is possible that they are
highly susceptible to FIV not as a direct result of their high
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expression of fCD4 but because they also express high levels of 
CD16.
71
6. VACCINATION STUDIES-1
6.1. INTRODUCTION
As the value of FIV as a model for HIV infection in man is now 
well established (Pedersen et al, 1987, Olmsted et al, 1989,
Hosie and Jarrett, 1990), FIV can be used to investigate both the 
nature of a protective immunity against infection and the viral 
antigens which elicit protective immunity.
In an attempt to determine the role of humoral immunity in 
protection from FIV infection, cats were challenged with FIV-8 
after passive immunisation with anti-FIV antibodies. In an 
experiment to establish which viral antigens are important for 
protection, cats were immunised with ISCOMs containing the 
components of purified FIV. When there was a good serological 
response against the core proteins, the cats were challenged with 
FIV-8.
To test the efficacy of vaccination against FIV it was necessary 
to demonstrate protection from challenge with a known amount of 
virus. A large stock of FIV-8 was made and dispensed in aliquots 
at -70°C. This stock was titrated in cats to establish the 
minimum infectious dose and was subsequently used to test the 
efficacy of various immunisation strategies. After challenge, 
cats were monitored for evidence of infection by the detection of 
viraemia (by isolation of FIV from cultured peripheral blood T- 
cells) and by the development of antibodies to FIV proteins (by 
ELISA and immunoblotting). Attempts were made to detect FIV in 
tissues using the polymerase chain reaction (PCR). This would be 
a valuable additional test in vaccinated cats which were 
protected from viraemia after challenge.
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6.2. MATERIALS AND METHODS
6.2.1. Titration of FIV-8 in cats
Five groups of three 6 month old cats were used in this 
experiment. Each group was inoculated with tenfold dilutions of 
the FIV-8 stock, prepared as described in section 2.2.5. The cats 
were sampled at 0, 3, 6, 9, 12 and 17 weeks post infection. Serum 
was tested for the presence of antibody by ELISA and by 
immunoblotting. Virus isolation from the peripheral blood T-cells 
was attempted at 0, 3, 9 and 17 weeks post infection. Post-mortem 
examination of these cats was performed 9 months post infection. 
Samples of tissues were taken for histological examination and 
for the detection of FIV using PCR.
6.2.2. PCR protocol
To prepare tissues for amplification, pieces of frozen tissue of 
approximately 200mg were homogenised in liguid nitrogen and then
lysed in 500ul 1% Triton-X-100 in lOmM Tris (pH7) with ImM EDTA
for 20 minutes. Proteinase K was added to a final concentration 
of 500ug per ml and the samples were incubated at 37°C for 24 
hours. The samples were then left on ice for 4 hours after the
addition of 125ul 5M NaCl. After centrifugation, the high
molecular weight DNA was obtained by resuspending the pellet in 
lOOul deionised, distilled water (ddH20) and dialysing overnight 
in a large volume of ddH20. The supernatant was removed and the 
low molecular weight DNA was extracted using phenol and
chloroform followed by alcohol precipitation. The pellet thus
obtained was resuspended in lOOul ddH20.
Each PCR reaction was carried out with 50ul sample in a total
volume of lOOul using the Gene Amp kit (Perkin Elmer Cetus, 
Norwalk, CT). The final reaction mixture contained 50mM KC1, lOmM 
Tris-HCl pH 8.4, 1.5mM MgC12, 0.1% w/v gelatin, nucleoside
triphosphates (0.2M each) and Thermus aouaticus polymerase (1 
unit per reaction). Primers were added at a concentration of
73
0.5uM. The primers (1 TGG GAT GAG TAT TGG AAC CCT GAA 24 and 331 
TGC GAA GTT CTC GGC CCG GAT TCC 355) amplified a 355 base pair 
segment in the LTR of FIV. These primers were chosen as they were 
known to amplify a region which was highly conserved between the 
Petaluma and various Glasgow isolates of FIV (Fiona Thompson, 
personal communication).
Thirty cycles of DNA amplification were used, with a 1 minute 
denaturation step at 91°C, a 1 minute annealing step at 40°C and 
a 3 minute extension step at 70°C. Positive amplification 
controls were FIV-8 and FIV-14 LTRs cloned into the plasmid 
PIC19R (Fiona Thompson, personal communication).
6.2.3. Southern Hybridisation
Following amplification, lOul samples of each reaction mixture 
were added to 3ul loading dye (50% glycerol, 0.5% bromophenol 
blue, 0.5% xylene cyanol in 0.089M Tris borate, 0.089M boric 
acid, 0.002M EDTA (TBE)) and the fragments were resolved in a 1% 
agarose gel containing ethidium bromide (0.5ug per ml TBE), 
alongside DNA size markers (PhiX174 RF DNA-Hae III digest, 
BioLabs, New England).
After electrophoresis, the gel was examined under UV light for 
the presence of the 355 base pair LTR fragment and was 
photographed. The gel was then denatured for an hour in 1.5M 
NaCl, 0.5M NaOH, neutralised for an hour in 1M Tris HC1 pH8, 1.5M 
NaCl and then the DNA was transferred to a nylon membrane 
(Hybond-N, Amersham, UK) using the Southern blotting procedure as 
described by Maniatis et al [100]. The gel was then removed from 
the membrane and the loading wells were marked with a pencil. The 
membrane was wrapped in Saran film (Dow Chemical Company, UK) and 
placed under a UV lamp for 10 minutes.
The membrane was then placed in a sealed bag containing 
prehybridisation fluid (6 x SSC, 0.5% SDS, 5 x Denhardt's 
solution, lOOug per ml denatured salmon sperm DNA) and agitated
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in a water bath at 65°C for 4 hours. After incubation, a 
denatured ^2p_ labelled LTR probe was injected into the sealed 
bag, the bag was resealed and the probe was hybridised with the 
membrane overnight at 65°C. The probe was an FIV-8 LTR fragment 
(kindly provided by Fiona Thompson) which was labelled with 
[alpha-^P] dCTP (Amersham, UK) using a random primed DNA 
labelling kit (Molecular Biology Boehringer Mannheim) and 
purified using a NICK column (Pharmacia, Sweden).
After hybridisation, the membrane was removed from the bag and 
washed at 65°C in 2 x SSC, 0.5% SDS for 4 hours with several 
changes of buffer. The membrane was then autoradiographed.
6.2.4. Preparation of anti-FIV antibody
Serum was pooled from 5 cats which had been experimentally 
infected with FIV-8 for 9 months. All 5 cats were healthy and 
seropositive for FIV. The 100 ml of serum was heated twice to 
56°C for 30 minutes to inactivate virus and then spun in an SW21 
rotor over 20% sucrose at 21K for 3 hours. The upper lipid layer 
and pellet were discarded. The serum was added to 200ml of 0.06M 
sodium acetate and stirred before adding 7.5ml n-octanoic acid 
dropwise and continuing to stir for 30 minutes. The solution was 
spun at 2500 rpm for 20 minutes and the supernatant was filtered 
before dialysis against 0.154 sodium chloride. Finally, the 
antibody solution was concentrated to 25ml using polyethylene 
glycol.
To measure the antibody titre, five-fold dilutions of serum were 
tested for anti-FIV antibody by ELISA before and after treatment 
with n-octanoic acid. The titre was taken as the reciprocal of 
the last dilution to give a positive S/P ratio according to the 
manufacturer [71]. The titres obtained in the passively immunised 
cats were similarly measured.
A culture of T-cells was incubated with 2mls of antibody solution 
for 24 hours. The cells were then washed and the culture was
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monitored for evidence of viral infection for 14 days by visual 
examination for cytopathic effect and by ELISA for production of 
p24.
6.2.5. Preparation of ISCOMS
FIV-8 was grown in cat peripheral blood T-cells and clarified by 
centrifugation at 7.5K for 30 minutes before storage at -70°C. 
Four hundred mis of stored tissue culture fluid was thawed at 
37°C, added to the same volume of saturated ammonium sulphate and 
incubated at 4°C for 10 minutes before being centrifuged at 7.5K 
for 10 minutes. The pellets were resuspended to 18mls in Tris- 
saline and layered in two SW41 centrifuge tubes containing 0.8ml 
50% sucrose and 2.0mls 20% sucrose in PBS. The tubes were spun at 
30K for 2 hours and the virus bands were recovered in 1.5ml. The 
virus was then passed through a Sephadex G-25M column (column 
PD10, Pharmacia, Sweden) equilibrated with Tris-saline and 
recovered in 2.5ml. Aliquots were analysed by SDS-PAGE followed 
by either immunoblotting or Coomassie blue staining.
To prepare FIV-ISCOMS, 1.5ml of virus was added to the same 
volume of 4% decanoyl n methyl glucamide and incubated for an 
hour at 37°C to disrupt the virus. Lyophylised Quil A was added 
to a final concentration of 0.1% together with 150ul lipid mix 
(lOmg phosphatidyl choline, lOmg cholesterol per ml in 20% 
decanoyl n methyl glucamide in Tris-saline). The preparation was 
dialysed extensively over two days in 50mM ammonium acetate.
The purified virus was shown to contain the gag proteins p24 and 
pi7 as well as the precursor p55. There was also some envelope 
glycoprotein visible on the immunoblot (but not sufficient to be 
detectable by Coomasie blue staining).
The ISCOMs were analysed by electron microscopy and by density 
centrifugation on a 10 to 40% sucrose gradient at 35K for 12 
hours. Electron microscopy showed the typical regular cage-like 
structures, approximately 40nm in diameter (Figure 6.1). The
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Figure 6.1
E l e c t r o n  m i c r o g r a p h  o f  a  s a m p l e  f r o m  t h e  F I V - I S C O M  p r e p a r a t i o n  
( c o u r t e s y  o f  D r  H  L a i r d )
ISCOM preparation banded at a density of 1.087gml“*.
The composition of the virus ISCOMS is shown in the immunoblot in 
figure 6.2. The ISCOMs contained predominantly p24 as well as pi7 
and small amounts of p55 and gpl20. The relative concentrations 
of the proteins were determined using ovalbumin as a standard. A 
sample of the ISCOM preparation was run in a well alongside 
dilutions of ovalbumin in an SDS-PAGE gel and after 
electrophoresis the gel was stained with Coomassie blue stain. 
The degree of staining of the proteins in the ISCOM preparation 
was compared to that of the standards and the protein content was 
estimated to be approximately lOug of p24 and pl7 per dose. There 
was negligible gpl20 by Coomassie blue staining.
To determine the concentration of unincorporated Quil A in the 
FIV-ISCOM preparation, a method of rocket electrophoresis was 
used. Ten ul, 5ul and 2.5ul samples were electrophoresed in 150mM 
glycine, 20mM Tris buffer alongside tenfold dilutions of a 
reference standard of Quil A in a 0.8% agarose gel containing 2% 
sheep erythrocytes. After elecrophoresis the zone of haemolysis 
was directly proportional to the concentration of Quil A in the 
sample. By comparison with the standards, the level of 
unincorporated Quil A in the FIV-ISCOMs was estimated to be 
approximately lOug per dose.
6.2.6. Virus isolation
To isolate FIV, peripheral blood T-cells were grown from 
heparinised blood as described in section 2.2.2 and the culture 
was monitored for the production of FIV by examination for 
cytopathic effect, with confirmation by ELISA for p24 antigen or 
immunoblot analysis of cell lysate (as described in section
4.2.3).
6.2.7. Measurement of anti-FIV antibodies
A commercial ELISA kit was used to measure the serological
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Figure 6.2
I m m u n o b l o t  o f  a  s a m p l e  f r o m  t h e  F I V - I S C O M  p r e p a r a t i o n  s t a i n e d  
w i t h  a  p o l y c l o n a l  c a t  a n t i - F I V  s e r u m .
response to FIV and the responses to individual proteins were 
determined by immunoblotting (as described in section 4.2.3).
6.2.8. Measurement of anti-p24 antibodies
Antibodies against p24 were measured using an ELISA in which 
Immulon-I wells were coated overnight with 0.2ug recombinant p24 
protein which was produced by cloning the coding sequence for p24 
into pGEX and expressing the protein in Escherichia coli JM83
[84]. The wells were blocked with 2% NFMP in TBS for an hour and
washed twice in TBS. The sera was diluted 1 in 100 in 20% normal
goat serum, 2% NFMP, 0.5% Tween-20 in TBS and incubated in the
wells for one hour. The wells were washed 4 times with TBS and 
alkaline phosphatase conjugated goat-anti-cat immunoglobulin was 
incubated in the wells for one hour. After washing 6 times, 
disodium paranitrophenyl phosphate substrate was added and after 
30 minutes the absorbance at 405 nm was measured.
6.3. RESULTS
6.3.1. Titration in Cats
The pattern of seroconversion in the 5 groups of cats is shown in 
Table 6.1. At 17 weeks post infection all cats in groups 1 and 2 
and 1 out of 3 cats in each of groups 3 and 4 had seroconverted. 
None of the cats in group 5 seroconverted.
Virus could not be isolated from any of the cats at 0 or 3 weeks 
post infection. At 9 and 17 weeks post infection, virus could be 
isolated from all cats in groups 1 and 2, 1 of 3 cats in each of 
groups 3 and 4 and none of the cats in group 5. By applying the 
Karber formula and using viraemia at week 17 as the end-point, 
the ID50 was 2.2 x 10^ .
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Table 6.1
Proportions of seropositive cats after infection with tenfold 
dilutions of FIV-8
virus weeks post infection
dilution
0 3 6 9 12 17
10_z 0/3 0/3 3/3 3/3 3/3 3/3
1—* o 1 C
O
0/3 0/3 3/3 3/3 3/3 3/3
10-4 0/3 0/3 0/3 1/3 1/3 1/3
10'5 0/3 0/3 0/3 1/3 1/3 1/3
10~6 0/3 0/3 0/3 0/3 0/3 0/3
6.3.2. Histological examination of FIV-infected cats
The most striking lesion in the FIV-infected cats was
lymphadenopathy. This affected the pharyngeal and mesenteric 
nodes especially, as well as the Peyer's patches in the
alimentary tract and the bronchio-mediastinal nodes. There was a 
marked proliferation of the germinal centres which was
indistinguishable from the lesion seen in early HIV infection 
(WFH Jarrett, personal communication). Lesions also occurred in 
the gut associated lymphoid tissue (GALT), thymus, lung, spleen, 
myocardium, liver, kidney and bone marrow. Table 6.2 shows the 
distribution of the lesions in each cat examined. The number of 
cats with lesions and the severity of those lesions was greater 
in groups 1 and 2 which received the lowest dilutions of FIV.
6.3.3. Comparison of tissues for the detection of FIV
Lysates were made from samples of pancreas, bone marrow, lung, 
lymph node, kidney and spleen taken from an SPF cat and from a 
cat which had been experimentally infected with FIV-P for 9
months. Agarose gel electrophoresis of the PCR products displayed 
bands of approximately 355 base pairs in only two wells. These 
were the wells containing the reaction products from the positive 
control and the bone marrow of the FIV-infected cat. The two 
bands hybridised specifically with the FIV-8 LTR probe (Figure
6.3).
6.3.4. Detection of FIV in bone marrow of titration cats
Lysates were made from samples of bone marrow from 14 of the 15 
cats experimentally infected with tenfold dilutions of FIV-8 
(described in section 6.2.1). Agarose gel electrophoresis of the 
PCR products showed bands with the positive control, cat 1 in
group 1 and cat 3 in group 3. These bands hybridised specifically 
with the FIV-8 LTR probe. The autoradiograph also displayed LTR- 
specific bands in cats 2 and 3 in group 1, cats 2 and 3 in group 
2, cat 1 in group 3, and all cats in group 4 (Figure 6.4). These
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Table 6.2
a. Distribution of histological lesions in cats euthanased 9 
months post infection with tenfold dilutions of FIV-8; b. virus 
isolation (VI) and antibody status (Ab) of samples taken post­
mortem and c. detection of FIV in bone marrow biopsies using the 
polymerase chain reaction (PCR).
virus
dilution 10'2 10'•3 10"3 10'-4 10'5
Cat no. 1 2 3 1 2 3 I 2 3 1 2 3 1 2 3
a. Organs
CNS
a/c - - - - - + - - - - + - + +
GALT ++ ++ na na - ++ ++ - - + + ++ + ++
LNs ++ + ++ ++ ++ ++ ++ + - + ++ ++ + ++
Spleen ++ + ++ + + + ++ - - + + na + -
BM - - , - na na . + + - - na + - + -
Thymus ++ ++ + ++ ++ ++ ++ - - - + + - -•
Lungs + - + + - + + . + - + + + na -
Heart - - + + - - + - - - - - na -
Liver - - - - + + - - - + - na -
Kidneys - - - + - na + - - - na - na -
b. Blood
VI •+ + + + + + + - - - + - - -
Ab + + + + + + + - - - + - - -
c. PCR
BM + + + - + + + . + + + + - - na
- nothing abnormal detected 
+ pathological lesions present 
++ marked lesions present 
na tissue not available for examination
p bm I In s k +
355 bp
m.
Figure 6.3
S o u t h e r n  h y b r i d i s a t i o n  o f  P C R  p r o d u c t s  f r o m  p a n c r e a s  ( p ) ,  b o n e  
m a r r o w  ( b m ) ,  l u n g  ( 1 ) ,  l y m p h  n o d e  ( I n ) ,  s p l e e n  ( s )  a n d  k i d n e y  
(k).
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Figure 6.4
S o u t h e r n  h y b r i d i s a t i o n  o f  p r o d u c t s  f r o m  b o n e  m a r r o w  b i o p s i e s  o f  
c a t s  i n f e c t e d  w i t h  t e n f o l d  d i l u t i o n s  o f  F I V - 8 .  C a t s  1 t o  3  w e r e  
i n f e c t e d  w i t h  1 0 “ ^ ,  c a t s  4  t o  6  w i t h  1 0 “ ^ ,  c a t s  7 t o  9  w i t h  1 0 " ^ ,  
c a t s  1 0 - 1 2  w i t h  1 0 ' ®  a n d  c a t s  1 3  a n d  1 4  w i t h  1 0 " ®  d i l u t i o n s  o f  
F I V - 8 .
positives were not detected on the agarose gel. Table 6.2 shows a 
comparison of the antibody and virus status of the cats with the 
detection of FIV DNA in the bone marrow.
6.3.5. Passive immunisation of cats
Two 8 month old specific pathogen free cats were inoculated 
intravenously with 10mls of anti-FIV antibody. Two hours later 
the two immunised cats and 2 age-matched control cats which had 
not received antibody were challenged with 40 infectious units of 
FIV-8. The cats were blood sampled prior to immunisation, prior 
to challenge and at weekly intervals thereafter.
The titre of the serum prior to treatment with n-octanoic acid 
was 500 and after treatment was 2500. Samples from the passively 
immunised cats 2 hours post immunisation gave titres of 100. 
These titres were maintained one week later but there was no 
antibody at 2 weeks.
Virus isolation was attempted at weekly intervals after 
challenge. At 4 weeks post challenge, virus could be isolated 
from both of the passively immunised cats but not from either of 
the control cats. By 5 weeks post challenge, virus could be 
isolated from all four cats.
6.3.6. Vaccination with FIV-ISCOM
6.3.6.1. Virus isolation
Four 5 month old specific pathogen free cats were inoculated 
subcutaneously with the FIV-ISCOM at 0 weeks, 5 weeks and 18 
weeks. These 4 cats, together with 4 age-matched unvaccinated 
controls, were challenged at 20 weeks with 20 infectious units of 
FIV-8. At 3 weeks post challenge 3 out of 4 vaccinated cats and 
one out of 4 control cats were virus-positive (Figure 6.5). By 5 
weeks, all of the vaccinated cats and all but one of the control 
cats were virus-positive (Figure 6.6). There was no change up to
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Figure 6.5
I m m u n o b l o t  o f  c e l l  l y s a t e s  o f  p e r i p h e r a l  b l o o d  T - c e l l s  f r o m  
v a c c i n a t e d  a n d  c o n t r o l  c a t s  t a k e n  3  w e e k s  p o s t  c h a l l e n g e  a n d  
c u l t u r e d  f o r  1 4  d a y s .  T h e  i m m u n o b l o t  w a s  s t a i n e d  w i t h  a 
p o l y c l o n a l  c a t  a n t i - F I V  s e r u m .
8 weeks post challenge.
6.3.6.2. Production of anti-FIV antibodies
At 5 weeks the 4 vaccinated cats were antibody positive by ELISA 
and had antibodies to p55, p24 and pi7 on immunoblots. At 7 weeks 
the levels of antibodies to the core proteins were very high as 
shown by the immunoblots, especially to p24 and pi7, but there 
were no antibodies to gpl20 (Figure 6.7). All 4 vaccinated cats 
remained ELISA-positive for the remainder of the experiment.
After challenge the unvaccinated control cats were monitored by 
ELISA for anti-FIV antibodies. All 4 cats were antibody-negative 
at 3 and 5 weeks post challenge. Three out of 4 were antibody- 
positive at 7 weeks post challenge. These 3 cats remained ELISA- 
positive for the remainder of the experiment. The three 
seropositive cats had antibodies against both core and envelope 
proteins (Figure 6.7).
6.3.6.3. Production of anti-p24 antibodies
The absorbances of the sequential samples from the vaccinated 
cats and the controls are shown in figure 6.8. This graph shows 
that very high levels of anti-p24 antibodies were achieved by 
vaccination with FIV-ISCOM compared to the levels achieved after 
challenging the controls with 20 infectious units of FIV-8.
6.4. DISCUSSION
The end-point of the titration experiment was taken as the 
production of persistent viraemia after infection. Every cat 
which was viraemic at the end of the experiment was also 
seropositive. Using persistent viraemia as an end-point, the 
IDgQ was calculated as 2.2 x 10^  and hence suitable doses could 
be used to challenge immunised cats.
The comparison of various tissues as suitable templates for the
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I m m u n o b l o t  o f  c e l l  l y s a t e s  o f  p e r i p h e r a l  b l o o d  T - c e l l s  f r o m  
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S e q u e n t i a l  i m m u n o b l o t s  o f  s e r u m  s a m p l e s  f r o m  a c a t  v a c c i n a t e d  
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1 ) ,  b .  w e e k  5 ( i n o c u l a t i o n  2 ) ,  c . w e e k  7 ,  d . w e e k  8 ,  e . w e e k  1 1 ,
f . w e e k  1 8  ( i n o c u l a t i o n  3 ) ,  g . w e e k  2 0  ( c h a l l e n g e d ) ,  h . w e e k  2 3 ,
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Figure 6.8
Absorbances of samples taken from 4 cats vaccinated with FIV- 
ISCOMs (closed circles) and 4 control cats (open circles) in an 
ELISA for p24 antibodies. The cats were vaccinated at weeks 0, 5
and 18 and challenged at week 20.
detection of FIV using PCR showed that the tissue of choice was 
bone marrow. This may be due to bone marrow containing less 
fibrous tissue compared to the other tissues and therefore being 
more easily digested by the proteinase K to release viral DNA. On 
the other hand, it may suggest that FIV DNA is most abundant in 
the cells of the bone marrow. Indeed, it has been shown by in 
situ hybridisation that the platelet precursor cells, the 
megakaryocytes, contain high levels of FIV DNA (Niels Pedersen, 
personal communication).
It was possible to detect FIV DNA in three cats which were 
negative by virus isolation. This would suggest that PCR is a 
more sensitive technique compared to the assays which were 
available to detect virus after cultivation of peripheral blood 
T-cells. On the other hand PCR is such a sensitive technique that 
false positive results can arise from contamination [101]. The 
possibility of contamimation was minimised by handling the 
reagents using positive displacement pipettes in a laminar flow 
hood.
One cat which was positive by virus isolation was negative using 
PCR. It is possible that in this case there was less proviral 
DNA integrated in the bone marow cells. It has been shown that 
the sensitivity of PCR to detect HIV genome can be significantly 
increased by using nested primers [102]. Bracket primers may bind 
to a region of the host genome similar to the intended target 
viral sequence. This non-specific reaction is minimised by taking 
a portion of the product amplified using the bracket primers and 
adding it to a new reaction mix containing nested primers. The 
use of nested primers for the amplification of FIV DNA should 
therefore be investigated.
In this study it was possible to passively transfer anti-FIV 
antibody to recipient cats, achieving titres comparable to those 
seen in healthy seropositive cats. These titres were maintained 
for one week. In spite of this, the passively immunised cats were 
not protected from challenge with 40 infectious units of
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homologous virus. On the contrary, the virus isolation data 
suggest that there may have been enhancement of infection as 
virus could be isolated earlier from the cats which had received 
antibody compared to the controls.
Although it was possible to measure the titre of antibody 
achieved in the recipient cats by ELISA, the titre of 
neutralising antibodies was not known. It is posible that the 
neutralising antibody titre was inadequate to confer protection. 
Indeed the antibodies present in healthy seropositive cats may 
not be protective against infection. Administration of passive 
antibody has been successful against challenge with FeLV [103]. 
In addition, a study in which nine consistently HIV-antigen- 
positive patients were treated with hyperimmune plasma from 
healthy individuals with high anti-HIV titres resulted in 
sustained clearance of p24 antigen and clinical improvement in 
five patients [104]. It is possible, however, that the clearance 
of p24 was merely a result of the administered antibody masking 
the antigen from the assay. When chimpanzees were passively 
immunised with a preparation derived from plasma of HIV- 
seropositive donors, all animals became infected after challenge 
with 400 TCID50 of HIV. The HIV-positive plasma had high levels 
of virus neutralising antibody as measured by an in vitro 
neutralisation assay and the virus used to challenge the 
chimpanzees was the same strain of HIV as had been used in the 
neutralisation assay [105].
In the present study, immunisation with FIV-ISCOMs produced a 
good antibody response to the gag proteins of FIV as shown by 
immunoblotting and induced extremely high anti-p24 antibody 
titres. But even these high levels of anti-gag antibodies did not 
protect against challenge.
The FIV-ISCOM vaccine contained very low amounts of gpl20 and the 
vaccinated cats did not produce any anti-env antibodies. The 
major neutralising determinant of HIV is situated within the 
third hypervariable region, the V3 loop of the gpl20 protein
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[106]. Therefore it would appear (by analogy) that anti-env 
antibodies would be important in protecting against FIV
infection. Also, it is known that HIV gpl20 binds the host cell
receptor CD4 [107] and hence if an immune response interfered 
with this interaction then infecton could not occur. Furthermore, 
data from murine retrovirus systems indicate that protective 
immunity is induced by the envelope protein [108]. This would 
suggest that an effective vaccine against FIV should contain 
significant levels of envelope glycoprotein.
As in the passive immunisation experiment, there was a suggestion 
that after vaccination with FIV-ISCOMs there was enhancement of 
infection in the immunised cats, the vaccinated cats becoming
viraemic sooner after challenge than the controls. Antibody-
dependent enhancement of viral infection can occur in vitro by at 
least two mechanisms. The first is via Fc receptors on 
macrophages which mediate the uptake of virus complexed to
antibody. This has been demonstrated with HIV [99,109]. The 
second is via complement components which bind the antigen- 
anti body complex and interact with complement receptors on cells, 
resulting in infection of the cells with virus. This type of 
enhancement has been demonstrated with both HIV and SIV
[110,111]. To date, there have been no in vitro studies of 
antibody-dependent enhancement of FIV infection. The role of 
enhancement in lentivirus infections requires further
investigation as evidence is lacking that antibody-dependent
enhancement has importance in vivo. This study sugests that FIV 
may have an important role in the elucidation of the protective 
response against lentivirus infections.
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7. VACCINATION STUDIES-2
7.1. INTRODUCTION
The results of the immunisation with FIV-ISCOMs, together with 
the information available for HIV and SIV, suggested that it was 
important to include a source of gpl20 in a potential vaccine 
against FIV. As FIV-infected cells are a rich source of gpl20, in 
contrast to purified virus, it was proposed to use fixed, 
inactivated FIV-infected cells as the immunogen. In this way, it 
was hoped that the vaccinated cats would produce anti-env 
antibodies and would therefore be more likely to be protected 
from challenge. Attempts were also made to partially purify gpl20 
from FIV-infected cell lysates for incorporation into ISCOMs.
7.2. MATERIALS AND METHODS
7.2.1. Preparation of fixed, inactivated cells
FIV-8 was grown in cat PBTs. The cells were infected with FIV- 
infected tissue culture supernatant and uninfected cells were 
added three times at weekly intervals. The cells were harvested 
when the culture was producing a large virus yield, as shown by 
an ELISA for antigen production.
The cells were treated with glutaraldehyde using a modification 
of methods previously described [109,110]. The infected culture 
was spun at lOOOrpm for 5 mins, 6 x 10^ cells were resuspended in 
6ml ice cold Earle's balanced salt solution and 6mls 0.15% 
glutaraldehyde was added. The cells were left on ice for 5 mins 
and 12ml 0.1M glycine was added on ice. The cells were 
centrifuged at lOOOrpm for 5 mins, the supernatant was discarded, 
the cells were resuspended in 6ml of normal T-cell medium with 
10% DMS0 and 600ul Tris pH 8.0 and 13.2ul beta propiolactone were 
added. The cells were incubated at 37°C in the dark for 2 hours, 
dispensed into 200ul volumes and stored at -70°C.
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A volume containing 2 x 10® cells was washed and co-cultivated 
with 4 x 10® uninfected cells and the culture was maintained for 
one month. The culture was examined daily for the appearance of 
cytopathic effect and samples of tissue culture supernatant were 
taken at weekly intervals to be tested for FIV-antigen by ELISA 
There was no evidence of cytopathic effect after co-cultivation 
of the fixed, inactivated cells with uninfected cells for 4 
weeks. Similarly, the results of the weekly tests for antigen 
production were all negative.
For each dose of vaccine, 2 x 10® cells were thawed and washed 
twice in PBS. The cells were resuspended in 1ml PBS containing 
50ug Quil A and kept on ice until inoculation.
7.2.2. Gel Filtration
FIV-infected peripheral blood T-cells were harvested 3 days post­
infection and lysed in 1% Empigen-BB dipolar ionic detergent at a 
cell concentration of 4 x 10^ per ml. A fast protein liquid 
chromatography apparatus (Pharmacia, Sweden) was equilibrated 
with 50mM Tris containing 0.1% Empigen. Two 250ul samples were 
loaded onto a Superose-6 column (Pharmacia, Sweden) and the 
proteins were eluted in 1ml fractions. Fractions in the initial 
high molecular weight peak were retained, the apparatus having 
been calibrated so that the proteins in the initial peak had 
apparent molecular weights of greater than 80 kilodaltons (George 
Reid, personal communication). The fractions were concentrated 
before immunoblot analysis.
7.2.3. Affinity Chromatography
The fractions containing gpl20 were pooled and loaded onto a 
Lentil-Lectin-Sepharose 4B column which had been equilibrated 
with 50 mM Tris, 0.1% Empigen. The column was washed with 
equilibration buffer and any bound glycoprotein was eluted with 
50mM Tris, 0.1% Empigen and 50mM alpha-methyl mannoside.
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7.3. RESULTS
7.3.1. Vaccination wth cell vaccine
Five 10 week old specific-pathogen-free kittens were inoculated 
subcutaneously at 0, 3, 6, 9, 12, 15 and 18 weeks. Serum samples 
were taken at 3 weekly intervals for anti-FIV antibody testing by 
ELISA and by immunoblotting.
The 5 vaccinated cats and 5 age-matched control cats were 
challenged with 20 infectious units of FIV-8 at week 21. Prior to 
challenge, sera were tested for anti-env antibodies by 
radioimmunoprecipitaion of C^-glucosamine labelled P51 cells, 
using the method described in section 4.2.2. Virus isolation was 
attempted from the peripheral blood lymphocytes as described in 
section 6.2.5 at week 18, on the day of challenge and at 3 weekly 
intervals thereafter.
At 0 and 3 weeks post-immunisation all 5 vaccinated cats were 
negative for FIV-antibody by ELISA and immunoblotting. At 6 
weeks, 1 out of 5 cats was positive by ELISA and immunoblotting. 
By 9 weeks all 5 vaccinated cats were antibody-positive. Sera 
taken at week 15 contained antibodies against the env proteins 
gpl20 and gp41 in all 5 vaccinated cats, as shown in figure 7.1. 
Sequential samples from one of the vaccinated cats were tested by 
radioimmunoprecipitaion to determine when anti-env antibodies 
could first be detected. There was evidence of antibody at 6 
weeeks post-inoculation in this cat.
Sera taken prior to challenge were tested for neutralising 
antibody. All of the control cats and one of the vaccinated cats 
had no detectable neutralising antibody, 3 had titres of 25 and 
one had a titre of 200 (R. Osborne, personal communication).
All vaccinated and control cats were negative by virus isolation 
3 weeks prior to and on the day of challenge. By 3 weeks post- 
challenge, 4 of the 5 vaccinated cats and none of the controls
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Figure 7.1
R a d i o i m m u n o p r e c i p i t a i t i o n s  ( R I P A s )  o f  s e r a  w i t h  ^ C - g l u s o s a m i n e  
l a b e l l e d  F I V - 8 - i n f e c t e d  P 5 1  c e l l s .  L a n e s  a  t o  e  s h o w  t h e  R I P A s  o f  
s e r u m  t a k e n  a t  w e e k  1 5  f r o m  t h e  5  c a t s  i n o c u l a t e d  w i t h  t h e  
i n a c t i v a t e d  c e l l  v a c c i n e ,  l a n e  f  s h o w s  t h e  R I P A  o f  s e r u m  t a k e n  a t  
w e e k  1 5  f r o m  a n  u n v a c c i n a t e d  c o n t r o l  c a t  a n d  l a n e  g  s h o w s  t h e  
R I P A  t a k e n  f r o m  a c a t  9  m o n t h s  p o s t  e x p e r i m e n t a l  i n f e c t i o n  w i t h  
F I V - P .
were viraemic. By 6 weeks post-challenge, all 5 vaccinated cats 
and 4 of the 5 controls were viraemic.
7.3.2. Partial purification of gpl20
The gpl20 content at the various stages of purification are shown 
by immunoblot analysis in figure 7.2. The immunoblot illustrates 
that gpl20 can be purified successfully from the core proteins. 
Using this method, however, the efficiency of recovery was low 
and therefore it was not possible to obtain a sufficient quantity 
of purified envelope protein for incorporation into an ISCOM 
vaccine.
7.4 DISCUSSION
Since the efficiency of recovery of gpl20 is low using gel 
filtration and affinity chromatography, it appears to be 
difficult to achieve sufficient amounts for incorporation into 
ISCOMs using this system. As attempts to obtain large quantities 
of recombinant FIV envelope glycoprotein have not yet been 
successful, this study used inactivated FIV-infected cells as a 
vaccine containing significant amounts of gpl20. In this way it 
was possible to compare the responses of cats to inoculation with 
a vaccine containing predominantly core proteins with the 
responses to a vaccine containing both core and envelope 
proteins.
In SIV, various degrees of protection have ben achieved with 
different inactivated whole virus vaccines [35,36,37]. Desrosiers 
et al [35] used purified, detergent disrupted virus in muramyl 
dipeptide adjuvant. Two of six vaccinated monkeys were protected 
from viraemia after challenge with 200-1000 infectious units and 
5 of the 6 were protected from disease.
In contrast, Murphey-Corb et al [36] used formalin-inactivated 
gradient purified virus in muramyl dipeptide adjuvant. Eight of 
nine vaccinated monkeys were protected from challenge with 10
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Figure 7.2
I m m u r v o b l o t  a n a l y s i s  o f  s a m p l e s  t a k e n  a t  v a r i o u s  s t a g e s  i n  t h e  
p a r t i a l  p u r i f i c a t i o n  o f  g p 1 2 0 .  L a n e  a  s h o w s  t h e  c r u d e  l y s a t e ;  
l a n e s  b  a n d  c  t h e  t w o  f r a c t i o n s  c o l l e c t e d  f r o m  t h e  F P L C  
a p p a r a t u s ;  l a n e  d  t h e  f r a c t i o n  w h i c h  d i d  n o t  b i n d  l e n t i l - l e c t i n ;  
l a n e  e  t h e  m a t e r i a l  w h i c h  w a s  w a s h e d  f r o m  t h e  l e n t i l  l e c t i n  
c o l u m n ,  l a n e  f  t h e  m a t e r i a l  e l u t e d  w i t h  a l p h - m e t h y l  m a n n o s i d e ,  
l a n e  g  t h e  m a t e r i a l  w h i c h  w a s  w a s h e d  f r o m  t h e  c o l u m n  a n d  l a n e  h 
t h e  m a t e r i a l  o b t a i n e d  w h e n  t h e  l e n t i l  l e c t i n  w a s  b o i l e d  i n  
r e d u c i n g  s a m p l e  b u f f e r .
infectious units of SIV. The remaining animal showed a delay in 
developing disease.
In a third study, Gardner et al [37] used a beta-propiolactone 
inactivated virus vaccine. The monkeys were challenged with 10 
infectious units of SIV. There was protection in all 3 animals 
inoculated with vaccine in muramyl dipeptide adjuvant, in I of 
the 2 inoculated with vaccine in incomplete Freund's adjuvant and 
in 1 of 3 inoculated with vaccine and no adjuvant.
The differences between these observed protective efficacies may 
be explained by diferent immunisation schemes, choice of 
adjuvants or the route and dose of challenge. In all cases, the 
challenge virus was the same isolate of SIV as had been used in 
the vaccine preparation. More recent studies have shown 
protection against heterologous challenge with SIV (J. Stott and 
M. Cranage, personal communications).
In this study, a vaccine consisting of fixed, inactivated cells 
was produced which contained sufficient FIV envelope protein to 
induce anti-env antibodies. Furthermore, neutralising antibody 
was detectable in 4 of the 5 vaccinated cats prior to challenge. 
In spite of this, however, the vaccinated cats became viraemic 
after challenge. Indeed, as in the passive immunisation 
experiment and the vaccination experiment using FIV-ISCOMs, it 
appeared that after inoculation with the cell vaccine there was 
enhancement of infection in the immunised cats, the vaccinated 
cats becoming viraemic sooner after challenge than the controls.
There are several possible reasons which would explain the 
enhancement of FIV infection in this study whilst others have 
reported protection [54]. Similar discrepancies have been 
recorded with FeLV [111]. It has been shown that vaccination with 
FeLV envelope glycoprotein induces a protective immune response 
in the cat [112]. However, in one study, cats vaccinated with 
purified FeLV gp70 or gp85 developed antibodies against both 
gp70 and whole FeLV detectable by ELISA, but these antibodies did
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not neutralise the virus in vitro [111]. Also, the cats were more 
susceptible to infection with virulent FeLV compared to 
unvaccinated controls. It is possible (both in this FeLV 
experiment and in the FIV cell vaccine experiment described in 
this chapter) that non-neutralising antibodies formed complexes
with the challenge virus, increasing its uptake via Fc receptors 
on monocytes, macrophages and activated T-cells. This has been
demonstrated with West Nile virus [113], dengue virus [114] and 
HIV [27,99,115]. Alternatively, complement components which bind 
the antigen-anti body complex and interact with complement 
receptors on cells, may result in enhanced infection of the cells 
with virus. This type of enhancement has been demonstrated with 
both HIV and SIV [116,117].
It is possible that the use of different adjuvants could account 
for the differences in protection seen in this study (using Quil 
A) and in the study described by Yamamoto et al [54] (using 
threonyl muramyl dipeptide or a combination of Freund's complete 
and incomplete adjuvants). Quil A may activate the immune system, 
leading to an increased expression of Fc receptors as T-cells 
became activated and hence an increase in Fc receptor-mediated 
virus uptake. This would, however, be unlikely to explain the 
enhancement of infection by the FIV-ISCOM vaccination as there 
were no detectable anti-env antibodies produced and therefore no 
means of opsonising the virus for Fc receptor-mediated uptake. It 
has been shown that activated T-cells are more susceptible than 
resting T-cells to FIV infection in vitro (M. Hosie and B. 
Willett, unpublished observation) and therefore activation of the 
immune system in vivo by vaccination may simply lead to an 
enhancement of infection because more susceptible cells are 
available.
Also, the inactivation procedure may be important in maintaining 
the antigenicity of the viral proteins so that neutralising 
antibody-inducing epitopes are available in the vaccine 
preparation. Virus-enhancing and virus-neutralising epitopes have 
already been identified on the FeLV envelope glycoprotein [118].
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Therefore it will be important to identify epitopes on FIV which 
are responsible for inducing enhancing antibodies so that they 
can be excluded from potential vaccines.
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8. GENERAL DISCUSSION
The studies described in this thesis demonstrated the value of 
FIV as a model for HIV and used FIV in experiments towards the 
development of an effective vaccine. The similarities between FIV 
and HIV were established by the epidemiological study of the 
prevalence of FIV and FeLV in cats in the UK as well as the 
examination of the serological response to FIV infection.
The epidemiological study, described in chapter 3, demonstrated 
that FIV is a significant cause of disease in the cat. The
clinical signs of sick cats with FIV infection were analagous to 
those seen in HIV infection, namely non-specific signs such as 
lethargy, anorexia, weight loss, pyrexia and lymphadenopathy. The 
cats which were experimentally infected with FIV for the
calculation of the ID5Q (section 6.3.1) were examined
histopathologically approximately 6 months after infection. 
Examination of these tissues revealed lesions in the lymphoid 
tissues, kidney and lung which were strikingly similar to the
lesions reported in early AIDS patients (W Jarrett, personal
communication).
The data from the epidemiological survey were analysed to
determine those groups of cats most at risk of FIV infection in 
order to identify possible routes of transmission. Also, the 
prevalence of infection in multi-cat households was investigated 
to determine how readily transmission occurred between in-contact 
cats. The data revealed that free-roaming male cats are most at 
risk of infection and therefore biting was thought to be an 
important route of transmission. This route of infection is
analagous to HIV infection via intravenous drug use. Neither the 
epidemiological study nor examination of kittens born to
seropositive dams have shown evidence of transmission of 
infection to kittens, in utero, via colostrum or via milk [119]. 
In utero transmission, which occurs in HIV infection, is much 
less common in FIV infection. This may be because the feline 
placenta does not permit the intimate association which occurs
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between the maternal and foetal circulations in the human 
placenta. Sexual transmission of FIV has not been documented 
although it is possible to infect cats jDer vagina with FIV (D 
Harbour, personal communication).
The development of the serological response to FIV infection, 
described in chapter 4, was shown to parallel that of HIV
infection, with antibodies developing first against the core 
protein p24, followed by antibodies against the other core 
proteins pl7 and plO, the core precursor p55 and the envelope
glycoprotein gpl20. The use of immunoblotting identified
indeterminate sera with reactivity to one or two viral proteins
as had been seen in earlier studies with HIV (section 4.4).
Furthermore, the serological studies demonstrated that FIV 
infection, like HIV, was persistent.
The ultimate aim of these studies was to use FIV as a model for 
the development of a vaccine against HIV infection. Firstly, a 
challenge system was established to test the efficacy of 
candidate vaccines. Section 6.3.1 describes the experiment to 
calculate the IDgQ of FIV-8 which was subsequently used in 
challenge experiments. Cats were monitored for evidence of 
infection by virus isolation (section 5.1.3.2) and immunoblotting 
(section 4.3.2). Secondly, attempts were made to protect cats 
from infection by passive immunisation with antibody purified 
from FIV-8-infected cats. As this treatment did not confer 
protection in two recipient cats, it was concluded that either 
the antibodies in persistently infected cats are not protective, 
that the neutralising titres achieved were inadequate or that 
cell mediated rather than humoral immunity has a vital role in 
protection against infection. Finally, it was important to 
identify which viral components were necessary to induce a 
protective immune response. It was intended that three vaccine 
formulations would be compared; one containing FIV core proteins, 
another containing envelope proteins and a third with both core 
and envelope proteins.
•
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Although ultimately a vaccine would be likely to contain 
recombinant proteins, the sources of immunogens which were 
available during this study were either purified virus or virus- 
infected cells. As purified virus was a poor source of envelope 
proteins (section 4.3.2), it was thought that virus infected 
cells would be the best source of gpl20 for use in vaccines. 
Various cell lines were examined for the ability to support the 
growth of FIV-8 and FIV-P, as described in chapter 5.
There initially appeared to be a correlation between the ability 
of cells to support the growth of FIV-8 and the expression of the 
fCD4 marker. Thus, P51 and Q201 cells were more susceptible to 
FIV infection than peripheral blood T-cells and the cytopathic 
effect induced in P51 and Q201 cells was very marked. As P51 and 
Q201 cells were predominantly fCD4+ whereas peripheral blood T- 
cells contained both fCD4+ and fCD8+ cells, the role of fCD4 as 
the receptor for FIV was investigated. When attempts were made to 
correlate the presence of fCD4 on various cell lines with their 
ability to support the growth of FIV, however, the correlation 
was incomplete. Cell lines which were fCD4- (F422 and T3) 
supported the growth of FIV and cells which were fCD4+ (3201) 
could only be infected with difficulty.
Although FIV-8 grew well in Q201 cells, these were IL-2 dependent 
and were therefore expensive to grow in large cultures. Also, 
fresh uninfected cells were required to supplement infected 
cultures as the virus infection led to death of the susceptible 
cells. Other cell lines which supported the growth of FIV-8 were 
F422 and T3. These cell lines were IL-2 independent and grew 
rapidly in culture. Both lines, however, were productively 
infected with FeLV and were therefore thought to be unsuitable 
for the production of immunogens for vaccination. Similarly, P51 
cells had been shown to produce FeLV.
3201 cells had the advantage of being IL-2 independent and 
producing no FeLV. Despite expressing high levels of fCD4 on 
their surface, however, they could not be readily or reproducibly
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infected with FIV-8 (section 5.2.4). CRFK fibroblast cells have 
been used by others to produce large amounts of virus [50] but, 
like the 3201 cells, they could only be infected with FIV-8 with 
difficulty (although they were very readily infected with FIV 
derived from 3201 cells). Hence it appears that virus which is 
adapted for growth in cell lines such as 3201 and CRFK is 
different to field virus and may not, therefore, be ideal for the 
production of immunogens for vaccination studies. This hypothesis 
is supported by the finding that primary field isolates of FIV 
cannot be made directly onto CRFK cells; T-cells are required for 
the initial isolation and these must then be co-cultivated with 
CRFK cells. Even then, only a proportion of isolates will 
replicate in CRFK cells (K Siebelink, personal communication).
Hence, the cells which were chosen to produce FIV-8 for the 
vaccination studies were normal cat peripheral blood T-cells, 
normal cat thymocytes or Q201 cells. Despite requiring IL-2 and 
large numbers of fresh, susceptible cells, it was thought that 
the virus produced by these cells might be closer to field virus
compared to that produced by a cell line which could only become
infected after long-term co-cultivation.
Two candidate vaccines were tested in cats. The first was an 
ISCOM vaccine containing purified FIV-8 and is described in 
chapter 6. This vaccine was shown to contain mostly core proteins 
and a small amount of envelope protein. The cats made antibodies 
against the core proteins but not against the envelope proteins.
When they were challenged with homologous virus they became
viraemic, demonstrating that high levels of anti-core antibodies 
are not protective. Attempts were made to purify gpl20 in order 
to produce a vaccine containing envelope protein but insufficient 
material was obtained by the methods used. Therefore, the second 
vaccine was a fixed, inactivated cell vaccine and is described in 
chapter 7. It was hoped that this vaccine preparation would 
contain substantially more envelope protein than the ISCOM 
vaccine since infected cells retain more gpl20 than purified 
virus. The cats inoculated with this preparation developed
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antibodies against both core and envelope proteins but had only 
low neutralising antibody titres and were not protected upon
challenge.
Recent reports of the successful protection of monkeys against 
SIV infection [35,36,37] and of cats against FIV infection [54]
are encouraging in two respects. Firstly they demonstrate that
vaccination against lentiviruses is feasible. Secondly, they 
highlight the importance of animal models in studies towards HIV 
vaccination.
There are two important features which an animal model for HIV 
should ideally possess. Firstly, infection with the virus should 
be biologically similar to infection with HIV. Both FIV and SIV 
behave like HIV. All three viruses share a similar tropism for T- 
lymphocytes and macrophages and a decline in CD4 numbers is seen 
with the progression of all three infections [23,120,49]. 
Infection of rhesus and cynomologous macaques with SIV and 
infection of cats with FIV produces a disease resembling HIV 
pathologically. Secondly, large numbers of animals should be 
available for vaccine trials. The advantage of animal models is 
that vaccines can be tested for their ability to induce
protection from challenge. Protection tests are feasible in all 
animal model systems. The advantage of the feline and simian 
systems is that protection against disease can be determined. It 
is possible that vaccination will not protect against infection, 
but that the onset of clinical signs may be delayed or prevented.
The chimpanzee (Pan troglodytes), gibbon ape (Hvlobates spp) and 
rabbit are the only animals which can be persistently infected
with HIV-1 but none has shown signs of disease. It appears that
the chimpanzee may be a HIV-1 host adapted species which controls 
HIV infection by an unidentified species-specific cellular
mechanism which compartmentalises the virus [121]. An animal 
model using chimpanzees would be hampered by the expense and 
restricted availability of this endangered species. Nevertheless, 
chimpanzees remain likely to be used for vaccine testing prior to
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human trials. Mice with severe combined immunodeficiency (SCID 
mice) have been reconstituted with human lymphoid tissue [122] 
and can be infected with HIV, but with no signs of disease [123]. 
The value of the rabbit and SCID mice models remains to be 
demonstrated.
Under experimental conditions, using virus adapted to growth in 
simian cells, HIV-2 can be used to infect rhesus monkeys, baboons 
and mangabeys [123,124]. Although these animals became viraemic 
and seroconverted, no disease developed. Therefore these models 
would only be of use in vaccine trials for protection against 
infection, not disease.
The ungulate lentiviruses (VV, CAEV, EIAV and BIV) have several 
features in common with HIV. They induce chronic diseases after 
long latent periods, cause viraemia in the presence of a weak 
neutralising antibody response, infect cells of the 
monocyte/macrophage lineage and undergo extensive genetic 
mutation and antigenic drift. The diseases caused by the 
ungulate lentiviruses (in contrast to HIV, FIV and SIV) are not 
immunosuppressive. The progressive neurological signs which are 
caused by VV and CAEV may, however, have a similar pathogenesis 
to the encephalopathies associated with HIV infection. Therefore 
the ungulate lentiviruses are useful models to study certain 
aspects of the pathogenesis of infection and in vaccine
evaluation.
From this account of the animal model systems it is clear that
SIV is remarkably similar to HIV. Furthermore, there is striking
nucleotide homology between HIV-1, HIV-2 and SIV, suggesting that 
the simian and human immunodeficiency viruses arose from a common 
ancestor in recent evolutionary history. Genetically FIV has no 
close relative, but the organisation of its small ORFs is more 
closely related to VV than to HIV (J Neil, personal
communication). Despite the structural data indicating that FIV 
is more closely related to the ungulate lentiviruses than the 
primate lentiviruses, in all other aspects FIV resembles the
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primate immunodeficiency viruses. The pathogenesis and response 
to infection with FIV are indistinguishable from the response to 
HIV.
At present the simian model has been developed further than the 
feline model. Although there are relatively few immunological 
reagents available to characterise the immune response of the 
cat, these are gradually becoming available. The feline model has 
an advantage over the simian model as there as large numbers of
cats are naturally infected with FIV and these animals can 
provide useful material for study. Furthermore, for 
investigations under controlled conditions (such as vaccination 
experiments) experimental cats may be housed more cheaply than 
monkeys.
The animal challenge experiments which have so far been
successful have used inactivated whole virus, either in the form 
of purified virus or virus-infected cells [35,36,37,54]. It is 
important to identify which viral antigens are capable of 
eliciting protective immunity. To date, the structural components 
associated with the viral envelope of HIV have been studied most 
extensively.
The envelope is likely to be an important immunogen as it is
known that HIV gpl20 binds to the host cell receptor CD4
[23,24,25,26] and therefore an immune response interfering with 
the gpl20-CD4 interaction should prevent infection. Furthermore, 
the principal neutralising epitope of HIV is situated within the 
third hypervariable region, the V3 loop of gpl20 (amino acids 
296-331) [106].
The presence of antibodies against the V3 loop in sera of HIV- 
infected mothers and their uninfected children was significant. 
This suggested that anti-V3 loop antibodies were protective, 
preventing intrauterine transmission of HIV [125]. Berman et al 
[126] demonstrated that chimpanzees inoculated with recombinant 
gpl20 were protected from infection by HIV-1 whereas those
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inoculated with gpl60 were not. Neutralisation in vitro did not 
correlate with protection in vivo as high neutralising antibody 
titres were found in both groups. It may, however, be significant 
that at the time of challenge, the group inoculated with gpl20 
had higher titres to the V3 loop compared to the group inoculated 
with gpl60.
Another neutralistion epitope on the envelope is situated within 
the transmembrane component, gp41 (amino acids 735-752). This 
epitope is highly conserved and has been shown to be a potent 
immunogen in the rabbit [127]. Two characteristics of HIV-1 are 
important obstacles to to an effective vaccine. Firstly there is 
much genomic variability, especially in env, which could permit 
the virus to escape the host immune responses and lead to 
increased pathogenicity as disease advances [128,129]. Secondly 
HIV can be transmitted between cells without the release of free 
virus. This feature might be expected to make virus destruction 
difficult by means of antibody alone.
Although the relative contributions of cellular and humoral 
immunity in HIV-1 infection have not yet been defined, humoral 
immunity alone has not been protective in passive immunisation 
experiments in the chimpanzee [105,114] or in the cat (section 
6.3.5). It is therefore presumed that induction of strong T- 
lymphocyte immunity will be required for successful vaccination 
against HIV-1. Cytotoxic T-cells (CTL) eliminate virus-infected 
cells. The T-cell receptor on the CTL recognises viral protein 
fragments in combination with a major histocompatibility complex 
antigen molecule on the surface of the target cell. HIV-1- 
specific CTL are detectable in both peripheral blood and tissues 
of infected people and are aimed at multiple viral proteins
[130]. The precise epitopes recognised by these CTL are currently 
being defined.
A successful vaccine should elicit protective CTL which are able 
to destroy HIV-infected cells only. HIV-infected cells in vivo 
shed gpl20 which can bind CD4 on the surface of uninfected cells
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[131]. The envelope protein may then be taken up, processed and 
presented on the surface of the cell, resulting in lysis by 
CTL with possible deleterious effects [132].
Unlike neutralising epitopes which are present only on the 
structural proteins coating the virus particle, CTL epitopes can 
be present in virtually any structural or non-structural viral 
protein. The internal viral proteins of HIV-1 are far less 
heterogeneous than the envelope protein and may therefore be
better candidates for vaccination. There have been reports of 
gag-specific CTL, as well as pol-specific, ygf-specific and nef- 
specific CTL [130]. It is likely that other regulatory proteins 
will also be shown to be CTL targets. However, the results of 
the FIV-ISCOM vaccination experiment (section 6.3.6) demonstrated 
that FIV gag products alone were not sufficient for protection 
against FIV infection.
There are several candidate HIV vacines currently undergoing 
clinical trials in humans [133]. Phase 1 clinical trials in 
healthy volunteers assess safety and immunogenicity. Detailed
immunological analyses are made to characterise the elicited 
immunity and to check the absence of deleterious effect, such as 
immunosuppressive HIV components in the vaccine and the induction 
of autoimmune reactivity [134] or enhancing antibodies [99,114]. 
Vaccines currently undergoing phase 1 trials include a live
vaccinia recombinant expressing gpl60 [135], a subunit gpl60 
vaccine produced in a baculovirus expression system [136], a 
combination of these [137], a gpl20 vaccine produced in yeast 
[138] and synthetic peptides corresponding to part of the core 
protein pl7 [139]. All of these preparations were well tolerated 
and induced specific anti-HIV immune responses [138] but 
potential CTL responses generated by these vaccination protocols 
remain to be fully characterised.
Although tissue culture-derived material may be used 
experimentally in animal models to determine which components of 
the virus provide protection, recombinant molecular approaches
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will be necessary to generate a sufficient quantity of safe
immunogens for use in man. Various systems have been used to
express genes coding for HIV antigens. The large DNA viruses, 
such as vaccinia and adenoviruses, have been used as vectors for 
the generation of recombinant vaccines. Upon infection of the 
host, these viruses can replicate, amplify the foreign protein 
and efficiently present the protein to the immune system.
Vaccinia virus has been used successfully in vaccines against 
rabies and rinderpest [140] as well as in HIV vaccination 
experiments. There is, however, concern about the possible
development of post-vaccinal encephalitis in immunocompromised 
humans. Secondly, there is concern that individuals who have 
previously been vaccinated as part of the smallpox erradication 
programme will possess a pre-existing immunity to vaccinia which 
may limit viral proliferation and antigen production. Adenovirus 
vaccines have been demonstrated to be safe and efficacious, 
giving rise to asymptomatic adenovirus infection in humans and 
inducing immunity against adenoviral respiratory disease [139]. 
Sequences encoding gpl20 have been inserted into adenovirus
vectors but there is concern that severe infections may develop 
in immunocompromised individuals.
Hybrid polioviruses may also be used for antigen expression and 
delivery. The Sabin type 1 vaccine strain of poliovirus is 
probably the safest and most successful modified live vaccine 
virus used in humans. The poliovirus chimaera system allows the 
selective expression of defined regions of HIV proteins in an 
immunoprominent position and therefore enables specific immune 
responses to be induced [127].
The expression vector system plays a major role in the post- 
translational modification of the expressed protein. The 
recombinant clones expressed in gram-negative bacteria such as 
Escherichia coli or in yeasts are denatured and non- or 
incorrectly glycosylated respectively. Since the HIV envelope 
glycoproteins have been implicated in CD4 binding and syncytium
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formation [23,24,25], it would appear that glycosylation may be 
an important consideration in the design of a recombinant
vaccine. A mammalian system, Chinese hamster ovary cells, has
been used to express recombinant gpl20 which resembles native, 
viral gpl20 in glycosylation [141].
As most of the typical eukaryotic processes of protein post- 
translational modification also occur in insect cells (an
exception is the inability of insect cells to make complex-type 
glycans and to add sialyic acid), insect cells infected with 
recombinant baculoviruses have provided a valuable source of 
expressed proteins [142]. Baculovirus expression of the complete 
HIV gag gene resulted in the synthesis and release of enveloped 
particles containing unprocessed gag gene products [143].
While the production of gpl20 in mammalian cells provides a
closer molecular replica of the native viral antigen, it is 
possible that other expression systems may be used to produce 
useful, although conformationally incorect, forms of the protein. 
The production of the envelope glycoprotein in bacteria and yeast 
has the advantage of producing significantly higher quantities of 
antigen than mammalian cells. A 200 amino acid portion from the 
carboxy-terminal region of HIV gpl20 which was produced in 
Escherichia coli induced the production of neutralising 
antibodies [144]. This finding suggested that antigen 
conformation was not important for the induction of neutralising 
antibodies. However, other portions of gpl20 produced in bacteria 
did not induce neutralising antibodies. In addition, in contrast 
to results for recombinant mammalian-derived gpl20, antibodies 
directed against the bacterial antigen were completely type- 
specific [145]. Hence native gpl20 may induce the formation of a 
higher degree of cross-neutralising antibodies compared to the 
denatured gpl20 produced in bacteria.
Other potential HIV vaccine candidates are synthetic peptides. An 
important factor in the presentation of peptides is the presence 
of a helper T-cell epitope as well as the B-cell epitope against
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which antibody is to be directed. There is considerable evidence 
to support the concept that T-cells recognise a complex formed 
between major histocompatibility complex molecules on the host 
cell surface and the peptides derived from processed antigen. The 
helper T-cell epitopes on an antigen must be able to bind to the 
class II molecules on the host cell surface and subsequently 
interact with the T-cell receptor. It was previously assumed that 
it was necessary for a peptide to be attached to a carrier 
molecule for it to function as an antigen but it is now known 
that a peptide can elicit antibodies if it possesses a helper T- 
cell epitope suitable for the host species. Alternatively a 
synthetic peptide or fusion construct may be produced which 
combines peptide epitopes recognised by T-cells and neutralising 
epitopes [146].
Antigens produced by recombinant DNA technology will, in general, 
be monomers. It is becoming increasingly apparent that to be 
optimally immunogenic, antigens should be presented in several 
copies. For example, when expressed as a dimer or tetramer on 
beta-galactosidase or as a mutimer on the hepatitis B core, a 
peptide corresponding to a 20 amino acid sequence of a foot-and- 
mouth disease virus protein induced a response in guinea pigs 
which was two-fold greater than that induced by the peptide alone 
[147]. The use of the core antigen of hepatitis B in humans has 
several advantages. The protein subunit is a 21 kilodalton 
polypeptide which spontaneously assembles into characteristic 
27nm particles [148]. The core particle can be expressed in a 
wide range of systems, including bacterial, yeast, mammalian or 
via vaccinia virus and baculovirus. It is highly immunogenic as a 
result of its polymeric nature, the presence of a number of well- 
defined helper T-cell epitopes and its ablility to function as a 
T-cell independent antigen. This system, however, cannot be 
tested in cats.
Another carrier system is the Ty-virus-1ike particle (Ty-VLP). 
The yeast retrotransposon Ty encodes a set of proteins which are 
assembled into virus-like particles. The Ty particle DNA can
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tolerate the insertion of a wide range of additional protein 
sequence, allowing full-length proteins to be accomodated [149]. 
Hybrid Ty-VLPs can be purified easily, using the physical 
properties of the particle. Ty-VLPs containing the V3 loop of HIV 
gpl20 induced high titres of neutralising antibodies in rabbits 
and an HIV-specific T-cell proliferative response in mice after 
immunisation [150].
Several other carrier systems have been developed. Multimeric 
structures such as micelles and liposomes have been used. 
However, by incorporating an adjuvant into the antigen complex,
even greater resposes are induced. The only adjuvants authorised
for use in human vaccines are aluminium hydroxide and aluminium 
phosphate. These are, however, inferior to laboratory adjuvants 
(such as Freund's complete adjuvant) and do not consistently
elicit cell mediated immunity [151]. Therefore it is important to 
develop adjuvants which are as effective as Freund's complete 
adjuvant but which do not have its side-effect of inducing 
granulomas.
In the Syntex formulation the threonyl analogue of muramyl 
dipeptide is used with squalene [147]. This is a stable adjuvant 
and it induces the production of cytokines which potentiate the 
vaccine response [147]. But perhaps the greatest advances have 
been made with immunostimulating complexes (ISCOMs) in which the 
glycoside Quil A (an adjuvant which is used in conventional
vaccines) is incorporated into a complex together with the 
antigen, cholesterol and phosphatidyl choline [151]. Because the 
adjuvant is bound to the antigen, it can be used at drastically 
reduced concentrations. Quil A is a semi purified product from a 
crude saponin extract of the bark from the tree Quilla.ia 
saponaria Molina. It forms micelles which have regions accessible 
for hydrophobic interaction with amphipathic molecules such as 
membrane proteins. Membrane proteins from more than 20 different 
viruses have been isolated and incorporated into ISCOMs [152]. It 
has been shown that immunisation of cats with ISCOMs containing 
the membrane protein of FeLV induces protection [112].
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Furthermore, a single subcutaneous immunisation of mice with 
ISCOMs containing recombinant HIV envelope protein induced 
cytotoxic T-cells [153].
In this thesis the strategy for FIV vaccine experiments was to 
identify the viral proteins important for vaccination by 
constructing vaccines containing core proteins alone and core and 
envelope proteins together. Protection against FIV infection has 
only been demonstrated recently by others using inactivated whole 
virus or inactivated virus-infected cells [54]. Neither of the 
vaccines described in this thesis gave protection against 
infection. The cats immunised with the FIV-ISCOM vaccine 
(described in chapter 6) did not develop antibodies against the 
envelope protein, suggesting that env proteins may be the major 
determinants of immunity. However, some of the cats in the study 
described by Yamamoto et al [54] had anti-env antibodies and were 
not protected. Similarly the cats inoculated with the inactivated 
cell vaccine described in chapter 7 developed anti-env antibodies 
and were not protected. The levels of neutralising antibodies in 
these cats was low (section 7.3.1) and therefore future 
experiments will aim to achieve high levels of neutralising 
antibody prior to challenge.
This study highlights the importance of avoiding induction of 
sub-neutralising concentrations of antibodies as these may cause 
an enhancement of infection. In the vaccine experiments described 
in chapters 6 and 7 it appears that the low levels of antibody 
which were induced may have enhanced infection. Although the
necessary in vitro studies have not yet been carried out for FIV, 
in other virus systems, such as West Nile virus [112] and dengue 
virus [113], it has been shown that the binding of antibody-virus 
complexes to cellular Fc receptors facilitates the attachment of 
virus particles to target cells. In vitro studies using HIV
demonstrated that Fc receptors induced by cytomegalovirus allowed
immune complexes of HIV to infect fibroblasts which were
otherwise not permissive to HIV infection [27]. This finding 
suggested that antibody-mediated HIV infection of monocytes,
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macrophages and fibroblasts could occur in vivo. Enhancement of 
retroviral infection after vaccination was recorded in cats 
inoculated with purified FeLV envelope protein [111]. The cats 
developed antibodies against the envelope protein but these did 
not neutralise the virus in vitro and the cats were shown to be 
more susceptible to infection with FeLV compared to non­
vaccinated cats.
In chapter 5 the monoclonal antibody vpgl5 was shown to recognise 
the FIV receptor. If the preliminary evidence that vpgl5 binds 
the low affinity Fc receptor is substantiated, it is possible 
that the enhancement which was seen after vaccination with FIV- 
ISCOMs and the inactivated cell vaccine was not antibody- 
dependent. As the expression of the low affinity Fc receptor is 
increased in activated T-cells, it may be that the immunisation 
procedure itself resulted in an activation of the immune system, 
increased expression of the FIV receptor and hence an enhancement 
of challenge in the vaccinated cats compared to the unvaccinated 
controls. It will therefore be important in future experiments to 
include control cats which have been inoculated with a mock 
preparation in adjuvant. In this way it will be possible to test 
this hypothesis for the enhancement. Future vaccines will aim to 
induce significantly greater levels of neutralising antibodies 
with minimal activation of the immune system. With this 
consideration, it may be important to compare the effects of 
different adjuvants on the expression of the FIV receptor.
Future FIV vaccine experiments will aim to identify epitopes 
responsible for inducing neutralising and enhancing antibodies. 
Recombinant DNA technology will be used to produce defined 
regions of FIV proteins. This would allow a more systematic 
approach to be used to determine the viral components required 
for immunity. Recently, ISCOMs containing recombinant FIV p24 
have been inoculated into cats (G.Reid and 0. Jarrett, personal 
communication). The responses of the vaccinated cats were similar 
to the responses made by the cats vaccinated with the FIV-ISCOM 
described in chapter 6. High titres of anti-p24 antibodies were
106
induced but there was enhancement of infection, the vaccinated 
cats becoming infected sooner than the controls.
Other useful recombinant vaccines would contain gpl20 as this is 
the protein most likely to induce neutralising antibodies. It 
would be useful to compare gpl20 produced in various expression 
systems to determine whether or not it is necessary to have the 
correct pattern of glycosylation or the correct protein 
conformation for the induction of protective immunity. Similarly 
it would be interesting to compare different delivery systems and 
adjuvants to directly compare their efficacies in the feline 
system.
As information becomes available for HIV, it is possible to 
extrapolate for FIV the regions of gpl20 which may be useful in 
vaccine experiments. For example the analagous region to the 
principle neutralising determinant within the V3 loop of HIV can 
be identified in FIV. Hence vaccination with the peptide encoded 
by this region may be expected to induce cross-neutralising 
antibodies, as has been described for HIV [154]. Eventually, when 
sequences for other B-cell, as well as helper T-cell and CTL 
epitopes have been characterised, these too will be expressed and 
used in FIV vaccination experiments.
It is therefore clear that this study demonstrates that the 
animal models are required to identify which proteins, and then 
which epitopes, are necessary for immunity. The animal models 
could also be used to compare different systems for antigen 
presentation and to determine the relative efficacies of various 
adjuvants. The studies described in this thesis illustrate the 
potential value of the feline model which will be valuable in 
achieving an understanding of those mechanisms which are 
important for successful vaccination against HIV.
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